<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/>
  <meta name="type" content="article"/>
  <meta name="category" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/06/2020.04.04.020925.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.04.020925v2"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.04.020925"/>
  <meta name="DC.Date" content="2020-04-06"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor. However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV). ATV is of high interest because of its bioavailability within the respiratory tract. Our results show that ATV could dock in the active site of SARS-CoV-2 Mpro, with greater strength than LPV. ATV blocked Mpro activity. We confirmed that ATV inhibits SARS-CoV-2 replication, alone or in combination with ritonavir (RTV) in Vero cells, human pulmonary epithelial cell line and primary monocytes, impairing virus-induced enhancement of IL-6 and TNF-α levels. Together, our data strongly suggest that ATV and ATV/RTV should be considered among the candidate repurposed drugs undergoing clinical trials in the fight against COVID-19."/>
  <meta name="DC.Contributor" content="Natalia Fintelman-Rodrigues"/>
  <meta name="DC.Contributor" content="Carolina Q. Sacramento"/>
  <meta name="DC.Contributor" content="Carlyle Ribeiro Lima"/>
  <meta name="DC.Contributor" content="Franklin Souza da Silva"/>
  <meta name="DC.Contributor" content="André C. Ferreira"/>
  <meta name="DC.Contributor" content="Mayara Mattos"/>
  <meta name="DC.Contributor" content="Caroline S. de Freitas"/>
  <meta name="DC.Contributor" content="Vinicius Cardoso Soares"/>
  <meta name="DC.Contributor" content="Suelen da Silva Gomes Dias"/>
  <meta name="DC.Contributor" content="Jairo R. Temerozo"/>
  <meta name="DC.Contributor" content="Milene Miranda"/>
  <meta name="DC.Contributor" content="Aline R. Matos"/>
  <meta name="DC.Contributor" content="Fernando A. Bozza"/>
  <meta name="DC.Contributor" content="Nicolas Carels"/>
  <meta name="DC.Contributor" content="Carlos Roberto Alves"/>
  <meta name="DC.Contributor" content="Marilda M. Siqueira"/>
  <meta name="DC.Contributor" content="Patrícia T. Bozza"/>
  <meta name="DC.Contributor" content="Thiago Moreno L. Souza"/>
  <meta name="article:published_time" content="2020-04-06"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the ongoing pandemic of 2019 CoV disease (COVID-19), which is leading to 10-times more deaths then other public health emergencies of international concern provoked by highly pathogenic CoV from the years 2002 and 2012. Besides social isolation, identification of the suitable clinically approved drugs to be repurposed could lead to short-term action to reduce mortality. The SARS-CoV-2 major protease (Mpro) is validated target over highly pathogenic CoV. HIV protease inhibitors, like lopinavir (LPV), also inhibit the 2002 SARS-CoV Mpro. However, limited evidence exist whether other clinically approved antiretroviral protease inhibitors may bind more efficiently to this enzyme to block SARS-CoV-2 replication. Among these substances, atazanavir (ATV) has documented bioavailability into the respiratory tract, motivating further evaluation on its ability to impair SARS-CoV-2 replication. Here, we describe that ATV docks stronger to SARS-CoV-2 Mpro active site than LPV, occupying the substrate cleft in the active side during the entire molecular dynamic analysis. ATV blocked Mpro activity in cell-free based assays at 10μM. In vitro assays with different cell types, Vero cells, human pulmonary epithelial cell line and human primary monocytes, confirmed that ATV, combined or not with RTV, inhibited SARS-CoV-2 replication. Moreover, these drugs performed better than chloroquine, recognized for its antiviral and anti-inflammatory activities, to reduce virus-induced IL-6 and TNF-α levels. Our data highlights that ATV and ATV/RTV could be considered among the repurposed drugs undergoing clinical trials against COVID-19.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.04.020925v2"/>
  <meta name="citation_id" content="2020.04.04.020925v2"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.04.020925"/>
  <meta name="citation_num_pages" content="28"/>
  <meta name="citation_article_type" content="Article"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.04.020925"/>
  <meta name="citation_author" content="Natalia Fintelman-Rodrigues"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Carolina Q. Sacramento"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Carlyle Ribeiro Lima"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Franklin Souza da Silva"/>
  <meta name="citation_author_institution" content="Laboratório de Biologia Molecular e Doenças Endêmicas"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="André C. Ferreira"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="Universidade Iguaçu"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Mayara Mattos"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Caroline S. de Freitas"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Vinicius Cardoso Soares"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author" content="Suelen da Silva Gomes Dias"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author" content="Jairo R. Temerozo"/>
  <meta name="citation_author_institution" content="Laboratório de Pesquisas em Timo"/>
  <meta name="citation_author" content="Milene Miranda"/>
  <meta name="citation_author_institution" content="Laboratório de Vírus Respiratório e do Sarampo"/>
  <meta name="citation_author" content="Aline R. Matos"/>
  <meta name="citation_author_institution" content="Laboratório de Vírus Respiratório e do Sarampo"/>
  <meta name="citation_author" content="Fernando A. Bozza"/>
  <meta name="citation_author_institution" content="Instituto Nacional de Infectologia Evandro Chagas"/>
  <meta name="citation_author_institution" content="Instituto D’or de Pesquisa e Ensino"/>
  <meta name="citation_author" content="Nicolas Carels"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author" content="Carlos Roberto Alves"/>
  <meta name="citation_author_institution" content="Laboratório de Biologia Molecular e Doenças Endêmicas"/>
  <meta name="citation_author" content="Marilda M. Siqueira"/>
  <meta name="citation_author_institution" content="Laboratório de Vírus Respiratório e do Sarampo"/>
  <meta name="citation_author" content="Patrícia T. Bozza"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author" content="Thiago Moreno L. Souza"/>
  <meta name="citation_author_institution" content="Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC)"/>
  <meta name="citation_author_institution" content="National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDNP), Center for Technological Development in Health (CDTS)"/>
  <meta name="citation_author_email" content="tmoreno@cdts.fiocruz.br"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0003-2212-3899"/>
  <meta name="citation_reference" content="Masters, P. S. The molecular biology of coronaviruses. Adv. Virus Res. 66, 193–292 (2006)."/>
  <meta name="citation_reference" content="Cui, J., Li, F. &amp;; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192 (2019)."/>
  <meta name="citation_reference" content="Lam, T. T.-Y. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature (2020) doi:10.1038/s41586-020-2169-0."/>
  <meta name="citation_reference" content="WHO | Middle East respiratory syndrome coronavirus (MERS-CoV). WHO http://www.who.int/emergencies/mers-cov/en/ (2020)."/>
  <meta name="citation_reference" content="WHO | Severe Acute Respiratory Syndrome (SARS). WHO https://www.who.int/csr/sars/en/ (2020)."/>
  <meta name="citation_reference" content="Dong, E., Du, H. &amp;; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 0, (2020)."/>
  <meta name="citation_reference" content="Romer, P. &amp;; Garber, A. M. Opinion | Will Our Economy Die From Coronavirus? The New York Times (2020)."/>
  <meta name="citation_reference" content="Harrison, C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. (2020) doi:10.1038/d41587-020-00003-1."/>
  <meta name="citation_reference" content="Organization, W. H. WHO R&amp;;D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020. (2020)."/>
  <meta name="citation_reference" content="De Clercq, E. &amp;; Li, G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 29, 695–747 (2016)."/>
  <meta name="citation_reference" content="Wu, C.-Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U. S. A. 101, 10012–10017 (2004)."/>
  <meta name="citation_reference" content="Fehr, A. R. &amp;; Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. Clifton NJ 1282, 1–23 (2015)."/>
  <meta name="citation_reference" content="Gong, Y. et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin. Drug Metab. Toxicol. 15, 417–427 (2019)."/>
  <meta name="citation_reference" content="Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. (2020) doi:10.1056/NEJMoa2001282."/>
  <meta name="citation_reference" content="Stanley, T. L. et al. Effects of Switching from Lopinavir/ritonavir to Atazanavir/ritonavir on Muscle Glucose Uptake and Visceral Fat in HIV Infected Patients. AIDS Lond. Engl. 23, 1349–1357 (2009)."/>
  <meta name="citation_reference" content="Gibert, C. L. Treatment Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: An Update. Fed. Pract. 33, 31S–36S (2016)."/>
  <meta name="citation_reference" content="Dayer, M. R. Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective. 16."/>
  <meta name="citation_reference" content="Gautam, N. et al. Preclinical pharmacokinetics and tissue distribution of longacting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57, 3110–3120 (2013)."/>
  <meta name="citation_reference" content="Song, S. et al. Protective Effect of Atazanavir Sulphate Against Pulmonary Fibrosis In Vivo and In Vitro. Basic Clin. Pharmacol. Toxicol. 122, 199–207 (2018)."/>
  <meta name="citation_reference" content="Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)."/>
  <meta name="citation_reference" content="Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 105949 (2020) doi:10.1016/j.ijantimicag.2020.105949."/>
  <meta name="citation_reference" content="Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054–1062 (2020)."/>
  <meta name="citation_reference" content="Newton, A. H., Cardani, A. &amp;; Braciale, T. J. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin. Immunopathol. 38, 471–482 (2016)."/>
  <meta name="citation_reference" content="Solomon, T., Baylis, M. &amp;; Brown, D. Zika virus and neurological diseaseapproaches to the unknown. Lancet Infect Dis 16, 402–4 (2016)."/>
  <meta name="citation_reference" content="de Freitas, C. S. et al. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl Trop Dis 13, e0007072 (2019)."/>
  <meta name="citation_reference" content="Ferreira, A. C. et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother (2018) doi:10.1128/aac.01389-18."/>
  <meta name="citation_reference" content="Ferreira, A. C. et al. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci. Rep. 7, 9409 (2017)."/>
  <meta name="citation_reference" content="Sacramento, C. Q. et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 7, 40920 (2017)."/>
  <meta name="citation_reference" content="Figueiredo-Mello, C. et al. Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study). BMJ Open 9, e027207 (2019)."/>
  <meta name="citation_reference" content="UN health chief announces global ‘solidarity trial’ to jumpstart search for COVID-19 treatment. UN News https://news.un.org/en/story/2020/03/1059722 (2020)."/>
  <meta name="citation_reference" content="Jin, Y.-H. et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res. 7, 4 (2020)."/>
  <meta name="citation_reference" content="Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 1–14 (2020)."/>
  <meta name="citation_reference" content="Lv, Z., Chu, Y. &amp;; Wang, Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIVAIDS Auckl. NZ 7, 95–104 (2015)."/>
  <meta name="citation_reference" content="Huang, J. et al. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 879, 2332–2338 (2011)."/>
  <meta name="citation_reference" content="Beck, B. R., Shin, B., Choi, Y., Park, S. &amp;; Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv 2020.01.31.929547 (2020) doi:10.1101/2020.01.31.929547."/>
  <meta name="citation_reference" content="Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100, 13190–13195 (2003)."/>
  <meta name="citation_reference" content="Macchiagodena, M., Pagliai, M. &amp;; Procacci, P. Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling. (2020)."/>
  <meta name="citation_reference" content="Gao, R. et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis. Am J Pathol 183, 1258–68 (2013)."/>
  <meta name="citation_reference" content="Peschke, T., Bender, A., Nain, M. &amp;; Gemsa, D. Role of macrophage cytokines in influenza A virus infections. Immunobiology 189, 340–55 (1993)."/>
  <meta name="citation_reference" content="Channappanavar, R. &amp;; Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017)."/>
  <meta name="citation_reference" content="Monteerarat, Y. et al. Induction of TNF-alpha in human macrophages by avian and human influenza viruses. Arch Virol 155, 1273–9 (2010)."/>
  <meta name="citation_reference" content="Reed, H. L. J.,. &amp;;. Muench. A simple method of estimating fifty percent endpoints. Am J Hyg. (1938)."/>
  <meta name="citation_reference" content="CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html (2020)."/>
  <meta name="citation_reference" content="Jakalian, A., Jack, D. B. &amp;; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 23, 1623–1641 (2002)."/>
  <meta name="citation_reference" content="Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. &amp;; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157–1174 (2004)."/>
  <meta name="citation_reference" content="Allen, W. J. et al. DOCK 6: Impact of new features and current docking performance. J. Comput. Chem. 36, 1132–1156 (2015)."/>
  <meta name="citation_reference" content="Jin, Z. et al. Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. bioRxiv 2020.02.26.964882 (2020) doi:10.1101/2020.02.26.964882."/>
  <meta name="citation_reference" content="Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004)."/>
  <meta name="citation_reference" content="Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781–1802 (2005)."/>
  <meta name="citation_reference" content="MacKerell, A. D., Banavali, N. &amp;; Foloppe, N. Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56, 257–265 (2000)."/>
  <meta name="citation_reference" content="Zhang, T., Nguyen, P. H., Nasica-Labouze, J., Mu, Y. &amp;; Derreumaux, P. Folding Atomistic Proteins in Explicit Solvent Using Simulated Tempering. J. Phys. Chem. B 119, 6941–6951 (2015)."/>
  <meta name="citation_reference" content="Hoang Viet, M., Derreumaux, P. &amp;; Nguyen, P. H. Communication: Multiple atomistic force fields in a single enhanced sampling simulation. J. Chem. Phys. 143, 021101 (2015)."/>
  <meta name="citation_reference" content="Lindorff-Larsen, K., Piana, S., Dror, R. O. &amp;; Shaw, D. E. How fast-folding proteins fold. Science 334, 517–520 (2011)."/>
  <meta name="citation_reference" content="Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. &amp;; Klein, M. L. Comparison of simple potential functions for simulating liquid water. (1998) doi:1.445869."/>
  <meta name="citation_reference" content="Darden, T., York, D. &amp;; Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092 (1993)."/>
  <meta name="citation_reference" content="Heussen, C. &amp;; Dowdle, E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102, 196–202 (1980)."/>
  <meta name="citation_reference" content="Alves, C. R., Marzochi, M. C. &amp;; Giovanni-de-Simone, S. Heterogeneity of cysteine proteinases in Leishmania braziliensis and Leishmania major. Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas E Biol. 26, 167–171 (1993)."/>
  <meta name="twitter:title" content="Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor. However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV). ATV is of high interest because of its bioavailability within the respiratory tract. Our results show that ATV could dock in the active site of SARS-CoV-2 Mpro, with greater strength than LPV. ATV blocked Mpro activity. We confirmed that ATV inhibits SARS-CoV-2 replication, alone or in combination with ritonavir (RTV) in Vero cells, human pulmonary epithelial cell line and primary monocytes, impairing virus-induced enhancement of IL-6 and TNF-α levels. Together, our data strongly suggest that ATV and ATV/RTV should be considered among the candidate repurposed drugs undergoing clinical trials in the fight against COVID-19."/>
  <meta name="og-title" property="og:title" content="Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor. However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV). ATV is of high interest because of its bioavailability within the respiratory tract. Our results show that ATV could dock in the active site of SARS-CoV-2 Mpro, with greater strength than LPV. ATV blocked Mpro activity. We confirmed that ATV inhibits SARS-CoV-2 replication, alone or in combination with ritonavir (RTV) in Vero cells, human pulmonary epithelial cell line and primary monocytes, impairing virus-induced enhancement of IL-6 and TNF-α levels. Together, our data strongly suggest that ATV and ATV/RTV should be considered among the candidate repurposed drugs undergoing clinical trials in the fight against COVID-19."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-06"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1231967 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-type-article hw-article-category-new-results"> 
  <div class="article fulltext-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2 class="">Abstract</h2>
    <p id="p-3">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor. However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV). ATV is of high interest because of its bioavailability within the respiratory tract. Our results show that ATV could dock in the active site of SARS-CoV-2 Mpro, with greater strength than LPV. ATV blocked Mpro activity. We confirmed that ATV inhibits SARS-CoV-2 replication, alone or in combination with ritonavir (RTV) in Vero cells, human pulmonary epithelial cell line and primary monocytes, impairing virus-induced enhancement of IL-6 and TNF-α levels. Together, our data strongly suggest that ATV and ATV/RTV should be considered among the candidate repurposed drugs undergoing clinical trials in the fight against COVID-19.</p>
   </div>
   <div class="section" id="sec-1">
    <h2 class="">1) Introduction</h2>
    <p id="p-5">Coronaviruses (CoVs) are single-stranded positive sense RNA viruses with large enveloped nucleocapsids that are able to infect a range of hosts including both animals and humans
     <sup>
      <a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>
     </sup>. Although a number of human CoV are known to circulate seasonally, two highly pathogenic variants emerged in the 21
     <sup>st</sup> century that cause life-threatening infection, the severe acute respiratory syndrome (SARS-CoV) and middle-east respiratory syndrome (MERS-CoV)
     <sup>
      <a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>
     </sup>. At the end of 2019, a novel variant of SARS-CoV (SARS-CoV-2) appeared in the citizens of the City of Wuhan, China that is believed to have spilled over to humans from animal reservoirs, most likely bats and/or pangolins
     <sup>
      <a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>
     </sup>. The novel 2019 CoV is phylogenetically closer to SARS-CoV (from the 2002 outbreak) than MERS-CoV (from 2012 outbreak) 
     <sup>
      <a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">2</a>,
      <a id="xref-ref-3-2" class="xref-bibr" href="#ref-3">3</a>
     </sup>. Both SARS- and MERS-CoV raised international public health concerns with rates of mortality of 10 and 35%, respectively
     <sup>
      <a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>,
      <a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>
     </sup>. Soon after its discovery, the contemporary SARS-CoV-2 became a pandemic threat, with the number of confirmed infections ramping up globally
     <sup>
      <a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>
     </sup>. To date, SARS-CoV-2 is responsible for 10 times more deaths than the total sum from SARS- and MERS-CoV, with more causalities daily that are continue to scale up
     <sup>
      <a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">6</a>
     </sup>.
    </p>
    <p id="p-6">Currently, the most effective response to the SARS-CoV-2 pandemic has been self-quarantining and social distancing to avoid contact between infected and uninfected individuals that can flatten the virus dissemination curve, which aim to reduce the burden on medical resources to prevent loss of service for those with the highest need. While these social actions can disrupt virus transmission rates, they are not expected to reduce the absolute number of infected individuals. Furthermore, these strategies are also provoking a severe reduction in global economic activity
     <sup>
      <a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>
     </sup>. To effectively combat the impact of SARS-CoV-2 on infected individuals, and society as a whole, it is essential to identify antiviral drugs for immediate use, as well as develop new drugs and a vaccine for long-term solutions to the disease associated with SARS-CoV-2 (COVID-19).
    </p>
    <p id="p-7">Repurposing of clinically approved drugs is the fastest pathway towards an effective response to a pandemic outbreak
     <sup>
      <a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>
     </sup>. Some of the most promising antiviral candidates against SARS-CoV-2 have been under investigation since the outbreak of SARS-CoV in 2002. Building on this continuous investigation, an unprecedented effort to run a global clinical trial, called SOLIDARITY, is ongoing under the auspicious of the World Health Organization (WHO) and the United Nations (UN)
     <sup>
      <a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>
     </sup>. This mega trial has been putting forward lopinavir (LPV)/ritonavir (RTV), in combination or not with interferon-β (IFN-β), chloroquine (CQ) and remdesivir to treat COVID-19
     <sup>
      <a id="xref-ref-9-2" class="xref-bibr" href="#ref-9">9</a>
     </sup>. LPV, RTV and remdesivir target viral enzymes, while the actions of CQ and IFN-β target host cells.
    </p>
    <p id="p-8">The most successful antiviral drugs often directly target viral enzymes
     <sup>
      <a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>
     </sup>. For CoVs, its major protease (Mpro) has been a promissing drug target for almost two decades, starting with early studies on 2002 SARS-CoV that showed this enzyme to be inhibited by LPV/RTV, inhibitors of HIV protease
     <sup>
      <a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>
     </sup>. Mpro is required during the CoV replication cycle to process viral polyprotein
     <sup>
      <a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>
     </sup>. Highly pathogenic CoVs contain two open reading frames, ORF1a and ORF1b, that are translated by host ribosomes into their two respective viral polyproteins, pp1a and pp1ab. ORF1a encodes two cysteine proteases, the papain-like protease (PLpro) and Mpro. While PLpro cuts the polyprotein at three sites, Mpro is responsible for cleavage at 11 another locations that, together, produce the 16 nonstructural proteins.
    </p>
    <p id="p-9">In a combined therapy of LPV with RTV, LPV is included as the principle antiviral compound and RTV as an inhibitor cytochrome p450
     <sup>
      <a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>
     </sup>. Although RTV can also display weak anti-protease activity, at current therapeutic dosages its activity enhances the plasmatic concentration of the main antiviral compound by its ability to block drug metabolism. However, in an open-label clinical trial using LPV/RTV against COVID-19, their combination showed a limited benefit for treated patients
     <sup>
      <a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>
     </sup>. In the early 2000s, another contemporary antiretroviral protease inhibitor, atazanavir (ATV), replaced LPV/RTV due to fewer side effects for the patients
     <sup>
      <a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>,
      <a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>
     </sup>. Contemporarily, 
     <em>in silico</em> evidence suggested that other HIV protease inhibitors would target SARS-CoV-2 Mpro better than LPV or RTV, that included ATV
     <sup>
      <a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>
     </sup>. Importantly, ATV has been described to reach the lungs after intravenous administration
     <sup>
      <a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>,
      <a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>
     </sup>. Moreover, a proposed secondary use of ATV to treat pulmonary fibrosis suggested that this drug could functionally reach the lungs
     <sup>
      <a id="xref-ref-19-2" class="xref-bibr" href="#ref-19">19</a>
     </sup>.
    </p>
    <p id="p-10">The seriousness of COVID19 and the need for an immediate intervention, along with this series of observations with LPV, RTV and ATV, motivated us to evaluate the susceptibility of SARS-CoV-2 to ATV. Since ATV is available as a clinical treatment alone or in combination with RTV, both therapies were studied here, which for the first time describes that SARS-CoV-2 Mpro is a target for ATV. Further, ATV alone or withRTV could inhibit viral replication in cell culture models of infection that also prevented the release of a cytokine storm-associated mediators. Our timely data highlights an additional therapeutic approach against COVID-19 that should be considered for clinical trials.</p>
   </div>
   <div class="section" id="sec-2">
    <h2 class="">2) Results</h2>
    <div id="sec-3" class="subsection">
     <h3>2.1) ATV docks into SARS-CoV-2 Mpro more spontaneously and stably than LPV</h3>
     <p id="p-11">The targeting of the enzyme Mpro from SARS-CoV-2 by both ATV and LPV was evaluated by molecular modeling using a representative structure (PDB:6LU7). As shown in 
      <a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a>, ATV occupied the S1* and S1 regions, whereas LPV occupied S1* and S2 regions with calculated free energy scores for LPV and ATV of −59.87 and - 65.49 Kcal/mol, respectively. The more spontaneous binding of ATV, suggested by its lower energy score, may be related to its projected ability to form hydrogens bonds with the amino acid residues Asn142, His164, and Glu166 in Mpro, whereas the binding of LPV depends on hydrophobic interactions (
      <a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2</a>).
     </p>
     <div id="F1" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F1.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="The active site of SARS-CoV-2 Mpro in the absence and presence of the inhibitors. A representative structure of Mpro (PDB:6LU7) was color coded to show the electrostatic potential of residues in the active site for negative (blue) and positive (red) charges. Panel A, the cavities of ligand interaction designated S1*, S1 and S2 in the absence of inhibitors. Panel B, placement of LPV (cyan) docked in the S1* and S2 regions of the active site. Panel C, placement of ATV (orange) docked in the S1* and S1 regions of the active site." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;The active site of SARS-CoV-2 Mpro in the absence and presence of the inhibitors.&lt;;/span&gt;; A representative structure of Mpro (PDB:6LU7) was color coded to show the electrostatic potential of residues in the active site for negative (blue) and positive (red) charges. Panel A, the cavities of ligand interaction designated S1*, S1 and S2 in the absence of inhibitors. Panel B, placement of LPV (cyan) docked in the S1* and S2 regions of the active site. Panel C, placement of ATV (orange) docked in the S1* and S1 regions of the active site.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 1." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F1.medium.gif" width="345" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 1." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F1.medium.gif" width="345" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 1." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 1.</span>
       <span class="caption-title">The active site of SARS-CoV-2 Mpro in the absence and presence of the inhibitors.</span>
       <p id="p-12" class="first-child">A representative structure of Mpro (PDB:6LU7) was color coded to show the electrostatic potential of residues in the active site for negative (blue) and positive (red) charges. Panel A, the cavities of ligand interaction designated S1*, S1 and S2 in the absence of inhibitors. Panel B, placement of LPV (cyan) docked in the S1* and S2 regions of the active site. Panel C, placement of ATV (orange) docked in the S1* and S1 regions of the active site.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
     <div id="F2" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F2.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Binding profile of antiretroviral drugs onto SARS-CoV-2 Mpro. Two-dimensional (2D) representations of the interactions of LPV (A) and ATV (B) in the Mpro active site based on a molecular docking analysis. Two hydrogen bonds are predicted between ATV and Mpro." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Binding profile of antiretroviral drugs onto SARS-CoV-2 Mpro.&lt;;/span&gt;; Two-dimensional (2D) representations of the interactions of LPV (A) and ATV (B) in the Mpro active site based on a molecular docking analysis. Two hydrogen bonds are predicted between ATV and Mpro.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 2." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F2.medium.gif" width="321" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 2." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F2.medium.gif" width="321" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 2." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 2.</span>
       <span class="caption-title">Binding profile of antiretroviral drugs onto SARS-CoV-2 Mpro.</span>
       <p id="p-13" class="first-child">Two-dimensional (2D) representations of the interactions of LPV (A) and ATV (B) in the Mpro active site based on a molecular docking analysis. Two hydrogen bonds are predicted between ATV and Mpro.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
     <p id="p-14">A molecular dynamic analysis revealed that the root-mean-square deviation (RMSD) for the SARS-CoV-2 Mpro backbone presented different conformations in complex with ATV or LPV (Figure S1). LPV was initially at a 3.8 Å distance from the catalytic residue Cys145 (Figure S2A and S3A), which after conformational changes extended to a distance equivalent to 7.17 Å (
      <a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3A</a> and 
      <a id="xref-fig-4-1" class="xref-fig" href="#F4">4A</a>) that is projected to most likely limit the extent of its antiviral inhibition. Another critical residue, His41, was satisfactorily at a distance of 2.89 Å from bound LPV (
      <a id="xref-fig-3-2" class="xref-fig" href="#F3">Figure 3A</a> and 
      <a id="xref-fig-4-2" class="xref-fig" href="#F4">4A</a>). While ATV did not interact with His41 or Cys145 (Figure S2B and S3B), its position remained stable within the active site independent of conformational changes displayed by the enzyme (
      <a id="xref-fig-3-3" class="xref-fig" href="#F3">Figure 3B</a> and 
      <a id="xref-fig-4-3" class="xref-fig" href="#F4">4B</a>). The steric occupation of the cleft in the enzymatic active site by ATV, which block the residues of the catalytic amino acids, can be explained by its stronger interactions with Mpro, compared to LPV, through multiple hydrogen bonds during stationary docking and molecular dynamics (Tables S1-S3).
     </p>
     <div id="F3" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F3.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Final positions of ATV and LPV on Mpro at the end of a molecular dynamic simulation. Representative images of the molecular dynamics after 100 ns of simulation. LPV (A) and ATV (B) are positioned in the Mpro active site at the end of 100 ns simulation." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Final positions of ATV and LPV on Mpro at the end of a molecular dynamic simulation.&lt;;/span&gt;; Representative images of the molecular dynamics after 100 ns of simulation. LPV (A) and ATV (B) are positioned in the Mpro active site at the end of 100 ns simulation.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 3." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F3.medium.gif" width="316" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 3." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F3.medium.gif" width="316" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 3." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 3.</span>
       <span class="caption-title">Final positions of ATV and LPV on Mpro at the end of a molecular dynamic simulation.</span>
       <p id="p-15" class="first-child">Representative images of the molecular dynamics after 100 ns of simulation. LPV (A) and ATV (B) are positioned in the Mpro active site at the end of 100 ns simulation.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
     <div id="F4" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F4.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Position profile of ATV and LPV during molecular dynamics. Two-dimensional (2D) representation of the interactions of LPV (A) and ATV (B) in the Mpro active site at the end of 100 ns molecular dynamic simulation." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Position profile of ATV and LPV during molecular dynamics.&lt;;/span&gt;; Two-dimensional (2D) representation of the interactions of LPV (A) and ATV (B) in the Mpro active site at the end of 100 ns molecular dynamic simulation.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 4." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F4.medium.gif" width="309" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 4." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F4.medium.gif" width="309" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F4.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 4." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F4.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 4.</span>
       <span class="caption-title">Position profile of ATV and LPV during molecular dynamics.</span>
       <p id="p-16" class="first-child">Two-dimensional (2D) representation of the interactions of LPV (A) and ATV (B) in the Mpro active site at the end of 100 ns molecular dynamic simulation.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-4" class="subsection">
     <h3>2.2) ATV inhibits SARS-CoV-2 Mpro enzymatic activity</h3>
     <p id="p-17">Next, we evaluated whether ATV could inhibit SARS-CoV-2 Mpro activity by partially purifying the enzyme in cellular fractions obtained from SARS-CoV-2-infected cells and performing zymographic profiles. To assure that the proteinase profiles were not dependent on cellular enzymes, similar fractions of mock-infected cells were also prepared for comparison. The results from cysteine proteinase zymographic profiles in gelatinolytic gels reveled a cellular related band of approximately 70 kDa under both conditions (
      <a id="xref-fig-5-1" class="xref-fig" href="#F5">Figure 5</a>, lanes Nil). This activity was blocked by the drug E-64, an epoxide that acts as an irreversible inhibitor of cysteine proteases (
      <a id="xref-fig-5-2" class="xref-fig" href="#F5">Figure 5</a>, lanes E-64). In the infected cells, a region of activity was observed between 31 and 38 kDa that was not present in the mock fraction. This zone of molecular weight is consistent with expected size of SARS-CoV-2 Mpro as was the inhibition of activity in this region by exposure of the gels to 10 μM of ATV, which did not affect the cellular cysteine proteinase at 70 kDa (
      <a id="xref-fig-5-3" class="xref-fig" href="#F5">Figure 5</a>, lanes ATV). Further confirmation of the presence and activity of SARS-CoV-2 Mpro in fractions from infected cells was obtained by treatment with RTV, which inhibited activity in the molecular range of 31-38 kDa without a change in the 70 kDa region (
      <a id="xref-fig-5-4" class="xref-fig" href="#F5">Figure 5</a>, lanes RTV). These data are consistent with predictions from the molecular modeling and dynamic analyses that suggested that ATV could bind and target the enzymatic activity of the Mpro encode by the novel 2019 CoV.
     </p>
     <div id="F5" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F5.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Inhibition of proteinase activity through an analysis of gelatinolytic activity. Vero cells were mock treated or infected with SARS-CoV-2 at an MOI of 0.1 for 48h before lysis and preparation of a cellular fraction. Fractions containing 12 [[#xB5]]g of total protein separated by electrophoresis followed by cutting the gels into their individual lanes that were incubated in 10 mM sodium acetate buffer (pH 5.5) in the absence (Nil) or presence of 10 [[#xB5]]M of E-64, ATV or RTV. Gelatinolytic bands indicative of enzymatic activity were revealed by negative staining with amide black solution. Molecular mass markers are indicated (kDa)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Inhibition of proteinase activity through an analysis of gelatinolytic activity.&lt;;/span&gt;; Vero cells were mock treated or infected with SARS-CoV-2 at an MOI of 0.1 for 48h before lysis and preparation of a cellular fraction. Fractions containing 12 [[#xB5]]g of total protein separated by electrophoresis followed by cutting the gels into their individual lanes that were incubated in 10 mM sodium acetate buffer (pH 5.5) in the absence (Nil) or presence of 10 [[#xB5]]M of E-64, ATV or RTV. Gelatinolytic bands indicative of enzymatic activity were revealed by negative staining with amide black solution. Molecular mass markers are indicated (kDa).&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 5." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F5.medium.gif" width="440" height="234"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 5." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F5.medium.gif" width="440" height="234"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F5.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 5." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F5.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 5.</span>
       <span class="caption-title">Inhibition of proteinase activity through an analysis of gelatinolytic activity.</span>
       <p id="p-18" class="first-child">Vero cells were mock treated or infected with SARS-CoV-2 at an MOI of 0.1 for 48h before lysis and preparation of a cellular fraction. Fractions containing 12 µg of total protein separated by electrophoresis followed by cutting the gels into their individual lanes that were incubated in 10 mM sodium acetate buffer (pH 5.5) in the absence (Nil) or presence of 10 µM of E-64, ATV or RTV. Gelatinolytic bands indicative of enzymatic activity were revealed by negative staining with amide black solution. Molecular mass markers are indicated (kDa).</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-5" class="subsection">
     <h3>2.3) SARS-CoV-2 is susceptible to ATV in different cell types</h3>
     <p id="p-19">We extended our investigation to the inhibition of SARS-CoV-2 replication by ATV using a range of different cellular systems. Vero cells are a well-known model system that produce high virus titers and display visual cytopathic effects to viral infections. ATV alone, or in combination with RTV, inhibited infectious virus production and SARS-CoV RNA levels in Vero cells (
      <a id="xref-fig-6-1" class="xref-fig" href="#F6">Figure 6A</a> and 
      <a id="xref-fig-6-2" class="xref-fig" href="#F6">B</a>, respectively). CQ was used as a positive control because of its inclusion in the SOLIDARITY trial due to its encouraging pre-clinical and clinical results against SARS-CoV-2 replication and COVID-19, respectively
      <sup>
       <a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>,
       <a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>
      </sup>. ATV/RTV was the most potent therapy tested; with an EC
      <sub>50</sub> of 0.5 ± 0.08 µM. ATV alone and CQ’s potencies were 2.0 ± 0.12 µM and 1.0 ± 0.07 µM, respectively. SARS-CoV-2 susceptibility to CQ is consistent with recent reports in the literature
      <sup>
       <a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>
      </sup>, validating our analysis. The ATV/RTV, ATV, and CQ cytotoxicity values, CC
      <sub>50</sub>, were 280 ± 3 µM, 312 ± 8 µM and 259 ± 5 µM, respectively. Our results indicate that the selectivity index (SI, which represents the ratio between the CC
      <sub>50</sub> and EC
      <sub>50</sub> values) for ATV/RTV, ATV and CQ were 560, 156 and 259, respectively, which shows that ATV/RTV has a high therapeutic potential that was greater than CQ.
     </p>
     <div id="F6" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F6.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="The antiviral activity of ATV and ATV/RTV against SARS-CoV-2. Vero (A and B) or A549 (C) cells were infected with SARS-CoV-2 at the MOI of 0.01 and exposed to indicated concentrations of the drugs. After 2 days, the viral replication in the culture supernatant was measured by TCID50/mL (A) or RT-PCR (B and C). The data represent means [[#xB1]] SEM of three independent experiments." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;&lt;;span class=&quot;;caption-title&quot;;&gt;;The antiviral activity of ATV and ATV/RTV against SARS-CoV-2.&lt;;/span&gt;; Vero (A and B) or A549 (C) cells were infected with SARS-CoV-2 at the MOI of 0.01 and exposed to indicated concentrations of the drugs. After 2 days, the viral replication in the culture supernatant was measured by TCID&lt;;sub&gt;;50&lt;;/sub&gt;;/mL (A) or RT-PCR (B and C). The data represent means [[#xB1]] SEM of three independent experiments.&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 6." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F6.medium.gif" width="304" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 6." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F6.medium.gif" width="304" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F6.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 6." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F6.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 6.</span>
       <span class="caption-title">The antiviral activity of ATV and ATV/RTV against SARS-CoV-2.</span>
       <p id="p-20" class="first-child">Vero (A and B) or A549 (C) cells were infected with SARS-CoV-2 at the MOI of 0.01 and exposed to indicated concentrations of the drugs. After 2 days, the viral replication in the culture supernatant was measured by TCID
        <sub>50</sub>/mL (A) or RT-PCR (B and C). The data represent means ± SEM of three independent experiments.
       </p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
     <p id="p-21">Since the results regarding the pharmacologic activity of ATV and ATV/RTV against SARS-CoV-2 replication in Vero cells were promising, we next investigated whether the proposed drug therapies could inhibit virus replication in a human epithelial pulmonary cell line (A549). ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 (
      <a id="xref-fig-6-3" class="xref-fig" href="#F6">Figure 6C</a>) compared to Vero cells (
      <a id="xref-fig-6-4" class="xref-fig" href="#F6">Figure 6B</a>). ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types (
      <a id="xref-fig-6-5" class="xref-fig" href="#F6">Figure 6B</a> and 
      <a id="xref-fig-6-6" class="xref-fig" href="#F6">C</a>). ATV/RTV, ATV and CQ EC
      <sub>50</sub> values to inhibit SARS-CoV-2 replication in A549 cells were 0.60 ± 0.05 µM, 0.22 ± 0.02 µM and 0.89 ± 0.02 µM, respectively. 
      <em>In vitro</em> results confirmed the rational that SARS-CoV-2 would be susceptible to ATV that included cells derived from the respiratory tract.
     </p>
    </div>
    <div id="sec-6" class="subsection">
     <h3>2.4) ATV prevents cell death and pro-inflammatory cytokine production in SARS-CoV-2-infected monocytes</h3>
     <p id="p-22">Recent reports on the COVID-19 outbreak have implicated that an increase in the levels of lactate dehydrogenase (LDH) and interleukin 6 (IL-6) is associated with mortality
      <sup>
       <a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>
      </sup>. Viral infection in the respiratory tract often trigger the migration of blood monocytes to orchestrate the transition from innate to adaptive immune responses
      <sup>
       <a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>
      </sup>. For these reasons, ATV and ATV/RTV were tested at suboptimal (1 μM) or optimal (10 μM) doses in a SARS-CoV-2-infection model utilizing human primary monocytes.
     </p>
     <p id="p-23">ATV/RTV and CQ were similarly efficient to inhibit viral replication in the human monocytes (
      <a id="xref-fig-7-1" class="xref-fig" href="#F7">Figure 7A</a>). Virus infection increased cellular mortality by 75%, which was prevented by ATV, at both doses tested, and by ATV/RTV, at 10 μM (
      <a id="xref-fig-7-2" class="xref-fig" href="#F7">Figure 7B</a>). As a control, detergent treatment completely destroyed all cells (
      <a id="xref-fig-7-3" class="xref-fig" href="#F7">Figure 7B</a>). Moreover, we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant, which ranged from 20- to 60-fold depending on the cell donor (
      <a id="xref-fig-7-4" class="xref-fig" href="#F7">Figure 7C</a>, open circles in nil-treated cells). The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 µM, ATV/RTV at both 1 and 10 µM and CQ at 10 µM (
      <a id="xref-fig-7-5" class="xref-fig" href="#F7">Figure 7C</a>). Another biomarker of uncontrolled pro-inflammatory cytokine response, TNF-α, was up-regulated 40-fold during virus infection (
      <a id="xref-fig-7-6" class="xref-fig" href="#F7">Figure 7D</a>). Only the combination of ATV/RTV could significantly prevent the induction of TNF-α release (
      <a id="xref-fig-7-7" class="xref-fig" href="#F7">Figure 7D</a>). Altogether, our results confirm that ATV and ATV/RTV should not be ignored as an additional therapeutic option against COVID-19.
     </p>
     <div id="F7" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F7.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="ATV and ATV/RTV impairs SARS-CoV-2 replication, cell death and cytokine storm in human primary monocytes. Human primary monocytes were infected at the indicated MOI of 0.01 and treated with indicated concentration of the compounds. After 24h, virus replication (A) and LDH release (B) as well as the levels of IL-6 (C) and TNF-[[#x3B1]] (D) were measured in the culture supernatant. The data represent means [[#xB1]] SEM of experiments with cells from at least three healthy donors. Differences with P " class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-882335055" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;&lt;;span class=&quot;;caption-title&quot;;&gt;;ATV and ATV/RTV impairs SARS-CoV-2 replication, cell death and cytokine storm in human primary monocytes.&lt;;/span&gt;; Human primary monocytes were infected at the indicated MOI of 0.01 and treated with indicated concentration of the compounds. After 24h, virus replication (A) and LDH release (B) as well as the levels of IL-6 (C) and TNF-[[#x3B1]] (D) were measured in the culture supernatant. The data represent means [[#xB1]] SEM of experiments with cells from at least three healthy donors. Differences with &lt;;em&gt;;P &lt;;&lt;;/em&gt;; 0.05 are indicates (*), when compared to untreated cells (nil).&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Figure 7." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F7.medium.gif" width="440" height="370"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Figure 7." src="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F7.medium.gif" width="440" height="370"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F7.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 7." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/04/06/2020.04.04.020925/F7.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Figure 7.</span>
       <span class="caption-title">ATV and ATV/RTV impairs SARS-CoV-2 replication, cell death and cytokine storm in human primary monocytes.</span>
       <p id="p-24" class="first-child">Human primary monocytes were infected at the indicated MOI of 0.01 and treated with indicated concentration of the compounds. After 24h, virus replication (A) and LDH release (B) as well as the levels of IL-6 (C) and TNF-α (D) were measured in the culture supernatant. The data represent means ± SEM of experiments with cells from at least three healthy donors. Differences with 
        <em>P &lt;;</em> 0.05 are indicates (*), when compared to untreated cells (nil).
       </p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
   </div>
   <div class="section" id="sec-7">
    <h2 class="">3) Discussion</h2>
    <p id="p-25">In these two decades of the 21st century, the human vulnerability to emerging viral diseases has been notable
     <sup>
      <a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>
     </sup>. The emergence of infectious disease highlights the undeniable fact that existing countermeasures are inefficient to prevent virus spill over and diseases outbreak. Preclinical data on the susceptibility of an emerging virus to clinically approved drugs can allow for the rapid mobilization of resources towards clinical trials
     <sup>
      <a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>
     </sup>. This approach proved feasible for combating the Zika, yellow fever and chikungunya outbreaks experienced in Brazil over the past 5 years, when our group demonstrated that sofosbuvir, a blockbuster drug against hepatitis C, could represent a compassionate countermeasure against these diseases
     <sup>
      <a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>–
      <a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>
     </sup>.
    </p>
    <p id="p-26">Currently, the rate of SARS-CoV-2 dissemination has become one of the most rapidly evolving pandemics known in modern times with the number of cases and deaths doubling every week and the peak of the pandemic has yet to arrive
     <sup>
      <a id="xref-ref-6-3" class="xref-bibr" href="#ref-6">6</a>
     </sup>. The existence of several ongoing clinical trials against COVID-19 reinforces the suggestion that drug repurposing represents the fastest approach to identify therapies to emerging infectious disease
     <sup>
      <a id="xref-ref-8-3" class="xref-bibr" href="#ref-8">8</a>
     </sup>. The WHO/UN, under the auspicious of the SOLIDARITY trial, have highlighted the most promising anti-CoV drugs, such as LPV/RTV with or without interferon-β, CQ and remdesivir
     <sup>
      <a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>
     </sup>. Here, we provide preclinical evidence that another HIV protease inhibitor, ATV, can inhibit the activity of a critical protease of SARS-CoV-2, Mpro, and that this inhibition can extend to a disruption of viral replication as well as the release of cytokine storm-associated mediators associated with viral infection. The results suggest that the performance of ATV could be better than LPV and strongly support that inclusion of ATV-based therapies in clinical trials for COVID-19 either alone, in combination with RTV or both.
    </p>
    <p id="p-27">Kaletra® is an LPV/RTV formulation from Abbot Laboratories that was approved by Food and Drug Administration (FDA) in 2000 and was evaluated for use in the treatment during the SARS-CoV outbreak in 2002 and again for MERS-CoV. Its continued evaluation with the SARS-CoV-2 outbreak is a logical choice due to the conservation of the Mpro among these highly pathogenic viruses
     <sup>
      <a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>,
      <a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>
     </sup>. Nevertheless, information on the susceptibility of SARS-CoV-2 to other antiviral protease inhibitors that have been approved since 2003 has been scarce.
    </p>
    <p id="p-28">ATV was approved in 2003, and become a wider prescribed drug among HIV-infected individuals, than LPV, including for critically ill patients
     <sup>
      <a id="xref-ref-16-2" class="xref-bibr" href="#ref-16">16</a>
     </sup>. ATV shows a safer profile than LPV in both short- and long-tem therapeutic regimens
     <sup>
      <a id="xref-ref-15-2" class="xref-bibr" href="#ref-15">15</a>,
      <a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>
     </sup>. ATV has a documented bioavailability to reach the respiratory tract
     <sup>
      <a id="xref-ref-18-2" class="xref-bibr" href="#ref-18">18</a>,
      <a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>
     </sup>, which lead to its proposed use against pulmonary fibrosis
     <sup>
      <a id="xref-ref-19-3" class="xref-bibr" href="#ref-19">19</a>
     </sup>. However, it is not currently under consideration for clinical trials against COVID-19.
    </p>
    <p id="p-29">The potencies of LPV and LPV/RTV against CoV are from 10 to 8 μM, respectively
     <sup>
      <a id="xref-ref-32-2" class="xref-bibr" href="#ref-32">32</a>
     </sup>. Based on our data, ATV and ATV/RTV are at least 10 times more potent. The ATV and ATV/RTV 
     <em>in vitro</em> potencies are comparable to other small molecule inhibitors of the SARS-CoV-2, such as remdesivir and CQ
     <sup>
      <a id="xref-ref-20-3" class="xref-bibr" href="#ref-20">20</a>
     </sup>. The improved potency of ATV, in comparison to LPV, may be at least in part due to its multiple hydrogen bond driven interactions within the Mpro active site. Other investigators have also recognized a wider range of interactions of ATV and Mpro compared to LPV
     <sup>
      <a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>,
      <a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>
     </sup>, although none provided functional evidence through phenotypic assays as presented here. Neither ATV nor LPV displayed any interactions with the catalytic dyad of Cys145 and His41 at the start of the molecular dynamic simulations. However, important interactions were observed at its end, such as LPV-His41 and ATV-Glu166. Glu166 is one of the residues that promotes the opeing of Mpro for its substrate to interact with the active site
     <sup>
      <a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>,
      <a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>
     </sup>.
    </p>
    <p id="p-30">LPV/RTV was the first line of defense for early patients with COVID-19
     <sup>
      <a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>
     </sup>. In patients with severe COVID-19, the open-labeled clinical trial with LPV/RTV revealed that treated patients had 5% less deaths and better clinical improvement then controls
     <sup>
      <a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a>
     </sup>. Throughout the course of this study, LPV/RTV-treated patients continued to shed SARS-CoV-2 at the same magnitude and duration of the control group
     <sup>
      <a id="xref-ref-14-3" class="xref-bibr" href="#ref-14">14</a>
     </sup>, limiting the enthusiasm on the part of the medical and scientific community for this therapeutic option. In this context, ATV and/or ATV/RTV should not be ignored in the treatment of this novel respiratory disease. Indeed, our results demonstrate that the potency of ATV and ATV/RTV potency against SARS-CoV-2 in A549 cells is likely to be consistent with their bioavailability in the lungs in experimental models
     <sup>
      <a id="xref-ref-18-3" class="xref-bibr" href="#ref-18">18</a>,
      <a id="xref-ref-34-2" class="xref-bibr" href="#ref-34">34</a>
     </sup>.
    </p>
    <p id="p-31">Highly pathogenic respiratory viruses, such as influenza A virus, have been associated with a cytokine storm that describes an uncontrolled pro-inflammatory cytokine response
     <sup>
      <a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a>,
      <a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>
     </sup>. Cytokine storms also seem to be highly relevant for pathogenic human CoVs
     <sup>
      <a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a>
     </sup>. Contemporary investigations on SARS-CoV-2 strongly suggest the involvement of cytokine storm with disease severity
     <sup>
      <a id="xref-ref-22-2" class="xref-bibr" href="#ref-22">22</a>
     </sup>. COVID-19 mortality is associated with enhanced IL-6 levels and consistent cell death, as measured by LDH release
     <sup>
      <a id="xref-ref-22-3" class="xref-bibr" href="#ref-22">22</a>
     </sup>. We showed that ATV and ATV/RTV decreased IL-6 release in SARS-CoV-2-infected human primary monocytes. Moreover, we also included in our analysis TNF-α, another hallmark of inflammation during respiratory virus infections
     <sup>
      <a id="xref-ref-22-4" class="xref-bibr" href="#ref-22">22</a>,
      <a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>
     </sup>. Our results reveled that cellular mortality and cytokine storm-associated mediators were reduced after treatment with the repurposed antiretroviral drugs used in this study.
    </p>
    <p id="p-32">Among the most promising anti-SARS-CoV-2 drugs, CQ, IFN-β and LPV displayed a higher toxic profile than ATV. Moreover, ATV and ATV/RTV have 
     <em>in vitro</em> antiviral potencies comparable to CQ and remdesivir, which were superior to LPV/RTV. In summary, our study highlights a new option among clinically approved drugs that should be considered in ongoing clinical trials for an effective treatment for COVID-19.
    </p>
   </div>
   <div class="section" id="sec-8">
    <h2 class="">Material and Methods</h2>
    <div id="sec-9" class="subsection">
     <h3>4.1. Reagents</h3>
     <p id="p-33">The antiviral ATV, ATV/RTV and CQ were received as donations from Instituto de Tecnologia de Fármacos (Farmanguinhos, Fiocruz). ATV/RTV was prepared in the proportion of 3:1 as the pharmaceutical pills are composed of 300 mg ATV and 100 mg RTV daily. ELISA assays were purchased from R&amp;;D Bioscience. All small molecule inhibitors were dissolved in 100% dimethylsulfoxide (DMSO) and subsequently diluted at least 10
      <sup>4</sup>-fold in culture or reaction medium before each assay. The final DMSO concentrations showed no cytotoxicity. The materials for cell culture were purchased from Thermo Scientific Life Sciences (Grand Island, NY), unless otherwise mentioned.
     </p>
     <p id="p-34">Triton X-100 (TX-100), 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS), 1,2,3-Propanetriol (glycerol), bovine serum albumin (BSA), Phosphate-buffered saline (PBS), N-benzyloxycarbonyl-l-phenylalanyl-l-arginine 7-amino-4-methylcoumarin (Z-FR-AMC; ε= 1.78 × 10
      <sup>4</sup> M
      <sup>−1</sup> cm
      <sup>−1</sup>), dithiothreitol (DTT) and trans-epoxysuccinyl-l-leucylamido(4-guanidino)butane (E-64) were purchased from Sigma Aldrich Chemical Co. (St. Louis, MO, USA). HiTrap Q FF anion exchange chromatography column (HiTrap Q FF) was purchase from GE Healthcare Life Sciences. Micro-bicinchoninic acid (BCA) protein assay kit was purchased from Pierce Chemical Co. (Appleton, WI). All other reagents were of analytical grade or better.
     </p>
    </div>
    <div id="sec-10" class="subsection">
     <h3>4.2. Cells and Virus</h3>
     <p id="p-35">African green monkey kidney (Vero, subtype E6) and A549 (human lung epithelial cells) cells were cultured in high glucose DMEM with 10% fetal bovine serum (FBS; HyClone, Logan, Utah), 100 U/mL penicillin and 100 μg/mL streptomycin (Pen/Strep; ThermoFisher) at 37 °C in a humidified atmosphere with 5% CO
      <sub>2</sub>.
     </p>
     <p id="p-36">Human primary monocytes were obtained after 3 h of plastic adherence of peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from healthy donors by density gradient centrifugation (Ficoll-Paque, GE Healthcare). PBMCs (2.0 × 10
      <sup>6</sup> cells) were plated onto 48-well plates (NalgeNunc) in RPMI-1640 without serum for 2 to 4 h. Non-adherent cells were removed and the remaining monocytes were maintained in DMEM with 5% human serum (HS; Millipore) and penicillin/streptomycin. The purity of human monocytes was above 95%, as determined by flow cytometric analysis (FACScan; Becton Dickinson) using anti-CD3 (BD Biosciences) and anti-CD16 (Southern Biotech) monoclonal antibodies.
     </p>
     <p id="p-37">SARS-CoV-2 was prepared in Vero E6 cells from an isolate contained on a nasopharyngeal swab obtained from a confirmed case in Rio de Janeiro, Brazil. Viral experiments were performed after a single passage in a cell culture in a 150 cm
      <sup>2</sup> flasks with DMEM plus 2% FBS. Observations for cytopathic effects were performed daily and peaked 4 to 5 days after infection. All procedures related to virus culture were handled in a biosafety level 3 (BSL3) multiuser facility according to WHO guidelines. Virus titers were determined as the tissue culture infectious dose at 50% (TCID
      <sub>50</sub>/mL). Virus stocks were kept in - 80 °C ultralow freezers.
     </p>
     <p id="p-38">The virus strain was sequenced to confirm the virus identity and its complete genome is publicly deposited (
      <a href="https://nextstrain.org/ncov">https://nextstrain.org/ncov</a>: Brazil/RJ-314/2020 or GISAID EPI ISL #414045).
     </p>
    </div>
    <div id="sec-11" class="subsection">
     <h3>4.3. Cytotoxicity assay</h3>
     <p id="p-39">Monolayers of 1.5 × 10
      <sup>4</sup> Vero cells in 96-well plates were treated for 3 days with various concentrations (semi-log dilutions from 1000 to 10 µM) of ATV, ATV/RTV or CQ. Then, 5 mg/ml 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2
      <em>H</em>-tetrazolium-5-carboxanilide (XTT) in DMEM was added to the cells in the presence of 0.01% of N-methyl dibenzopyrazine methyl sulfate (PMS). After incubating for 4 h at 37 °C, the plates were measured in a spectrophotometer at 492 nm and 620 nm. The 50% cytotoxic concentration (CC
      <sub>50</sub>) was calculated by a non-linear regression analysis of the dose– response curves.
     </p>
    </div>
    <div id="sec-12" class="subsection">
     <h3>4.4. Yield-reduction assay</h3>
     <p id="p-40">Cells were infected with a multiplicity of infection (MOI) of 0.01. Vero or A549 cells were infected at densities of 5 × 10
      <sup>5</sup> cells/well. Human primary monocytes were infected at density of 2-8 × 10
      <sup>5</sup> cells/well, depending on the endogenous characteristic of the cell donor. Infections were performed in 48-well plates for 2h at 37 °C. The cells were washed, and various concentrations of compounds were added to DMEM with 2% FBS. After 48h, supernatants were collected and harvested virus was quantified by real time RT-PCR and infectious titers by TCID
      <sub>50</sub>/mL. A variable slope non-linear regression analysis of the dose-response curves was performed to calculate the concentration at which each drug inhibited the virus production by 50% (EC
      <sub>50</sub>).
     </p>
    </div>
    <div id="sec-13" class="subsection">
     <h3>4.5. Virus titration</h3>
     <p id="p-41">Monolayers of Vero cells (2 × 10
      <sup>4</sup> cell/well) in 96-well plates were infected with a log-based dilution of supernatants containing SARS-CoV-2 for 1h at 37°C. Cells were washed, fresh medium added with 2% FBS and 3 to 5 days post infection the cytopathic effect was scored in at least 10 replicates per dilution by independent readers. The reader was blind with respect to source of the supernatant. A Reed and Muench scoring method was employed to determine TCID
      <sub>50</sub>/mL
      <sup>
       <a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42</a>
      </sup>.
     </p>
    </div>
    <div id="sec-14" class="subsection">
     <h3>4.6. Molecular detection of virus RNA levels</h3>
     <p id="p-42">The total RNA from a culture was extracted using QIAamp Viral RNA (Qiagen®), according to manufacturer’s instructions. Quantitative RT-PCR was performed using QuantiTect Probe RT-PCR Kit (Quiagen®) in an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Amplifications were carried out in 25 µL reaction mixtures containing 2× reaction mix buffer, 50 µM of each primer, 10 µM of probe, and 5 µL of RNA template. Primers, probes, and cycling conditions recommended by the Centers for Disease Control and Prevention (CDC) protocol were used to detect the SARS-CoV-2
      <sup>
       <a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a>
      </sup>. The standard curve method was employed for virus quantification. For reference to the cell amounts used, the housekeeping gene RNAse P was amplified. The Ct values for this target were compared to those obtained to different cell amounts, 10
      <sup>7</sup> to 10
      <sup>2</sup>, for calibration.
     </p>
    </div>
    <div id="sec-15" class="subsection">
     <h3>4.7. Measurements Inflammatory Mediators and cell death marker</h3>
     <p id="p-43">The levels of TNF-α, IL-6 and LDH were quantified in the monocyte supernatants from infected and uninfected cells. ELISA for TNF-α and IL-6 required 100 µL of supernatants to be exposed to capture antibody in 96-well plates. After a 2h incubation period at room temperature (RT), the detection antibody was added. Plates were incubated for another 2h at RT. Streptavidin-HRP and its substrate were added, incubated for 20 minutes and the optical density was determined using a microplate reader set to 450 nm.</p>
     <p id="p-44">Extracellular lactate dehydrogenase (LDH) was quantified using Doles® kit according to manufacturer’s instructions. Supernatant was centrifuged at 5,000 rpm for 1 minute, to remove cellular debris. A total of 25 µL of supernatant was placed into 96-well plates and incubated with 5 µL of ferric alum and 100 µL of LDH substrate for 3 minutes at 37 °C. Nicotinamide adenine dinucleotide (NAD, oxidized form) was added followed by the addition of a stabilizing solution. After a 10 min incubation, plates were measured in a spectrophotometer at 492 nm.</p>
    </div>
    <div id="sec-16" class="subsection">
     <h3>4.8. Molecular docking</h3>
     <p id="p-45">ATV (PubChem CID: 148192) and LPV (PubChem CID: 92727) were used as inhibitors of the SARS-CoV-2 Mpro. ATV and LPV were prepared using the Generalized Amber Force Field (GAFF) and their charges were obtained using the AM1-BCC loading scheme 
      <sup>
       <a id="xref-ref-44-1" class="xref-bibr" href="#ref-44">44</a>,
       <a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45</a>
      </sup>.
     </p>
     <p id="p-46">Molecular docking experiments were performed with DOCK 6.9
      <sup>
       <a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a>
      </sup> for identifying the binding site of the Mpro. SARS-CoV-2 Mpro structure was obtained from Protein Data Bank (RCSB PDB, 
      <a href="http://www.rcsb.org">http://www.rcsb.org</a>), under the accession code #6LU7 
      <sup>
       <a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47</a>
      </sup>. The active site region was identified by using a complexed peptide (N-[(5-methylisoxazol-3-yl)carbonyl]alanyl-l-valyl-n∼1∼-((1r,2z)-4-(benzyloxy)-4-oxo-1-{[(3r)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-l-leucinamide) as a guide. The creation of the DOCK 6.9 input files for docking was performed using Chimera 1.14
      <sup>
       <a id="xref-ref-48-1" class="xref-bibr" href="#ref-48">48</a>
      </sup>.
     </p>
     <p id="p-47">The docking of ligands was performed in a box of 10 Å edges with its mass center matching that of the complexed peptide. Each scan produced 20 conformations for each ligand with the best score being used for molecular dynamics simulations.</p>
    </div>
    <div id="sec-17" class="subsection">
     <h3>4.9. Molecular dynamics</h3>
     <p id="p-48">Since the tertiary structure (3D) of the SARS-CoV-2 Mpro is a homodimer, we focused the molecular dynamics only one chain, henceforward chain A. Molecular dynamics calculations were performed using NAMD 2.9
      <sup>
       <a id="xref-ref-49-1" class="xref-bibr" href="#ref-49">49</a>
      </sup> and Charmm27* force field
      <sup>
       <a id="xref-ref-50-1" class="xref-bibr" href="#ref-50">50</a>
      </sup> at pH 7, i.e., with deprotonated Glu and Asp, protonated Arg and Lys, and neutral His with a protonated Nε atom. This all-atom force field has been able to fold properly many soluble proteins
      <sup>
       <a id="xref-ref-51-1" class="xref-bibr" href="#ref-51">51</a>–
       <a id="xref-ref-53-1" class="xref-bibr" href="#ref-53">53</a>
      </sup>. The soluble proteins were centered in a cubic box of TIP3P water molecules
      <sup>
       <a id="xref-ref-54-1" class="xref-bibr" href="#ref-54">54</a>
      </sup>; the box extended 1.2 nm outside the protein on its four lateral sides, and the appropriate numbers of Na+ and Cl-ions were added to ensure system neutralization. The electrostatic interactions were calculated using the Particle Mesh Ewald method and a cutoff of 1.2 nm
      <sup>
       <a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55</a>
      </sup>. The same cutoff of 1.2 nm was used for the Van der Waals interactions. The non-bonded pair lists were updated every 10 fs. In what follows, the analysis is based on MD simulation of 100 ns at 310 K.
     </p>
    </div>
    <div id="sec-18" class="subsection">
     <h3>4.10. Protein extraction</h3>
     <p id="p-49">Protein extracts containing SARS-CoV-2 Mpro activity were obtained from Vero cell monolayers at 25 cm
      <sup>2</sup> flasks that were infected for 1h with an MOI of 0.1 at 37 °C and 5% CO
      <sub>2</sub>. After 1 or 2 days of infection, the supernatant was harvested and monolayers were washed 3 times with in sterile cold PBS (pH 7.2). Next, cells were suspended into 1 mL of lysis buffer (100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10% glycerol and 0.6% Triton X-100) and kept at 4 °C. The soluble protein fraction was isolated as the supernatant after centrifugation (100,000 x g, 30 min, 4 °C) and stored at −20°C until further use. The protein concentrations of the samples were determined using the BCA protein assay kit.
     </p>
    </div>
    <div id="sec-19" class="subsection">
     <h3>4.11. Zymographic assays</h3>
     <p id="p-50">Proteinases were assayed after electrophoresis on 10% SDS-PAGE with 0.1% copolymerized gelatin
      <sup>
       <a id="xref-ref-56-1" class="xref-bibr" href="#ref-56">56</a>
      </sup>. Briefly, the gels were loaded per slot with 12 μg of soluble proteins dissolved in Laemmli’s buffer, and following electrophoresis at a constant voltage of 200 V at 4°C, they were soaked for 1 h at 25 °C in washing buffer (0.1 mM sodium acetate buffer (pH 5.5) containing 2.5% TX-100). Proteinase activity was detected by incubating (16 h at 37 °C) the gels in reaction buffer (0.1 mM sodium acetate buffer pH 5.5 containing 1.0 mM DTT), in the presence and absence of same concentration of 10 µM of E-64, ATV, RTV or the ATV/RTV combination. Hydrolysis of gelatin was visualized by staining the gels with amido black 0.2%
      <sup>
       <a id="xref-ref-57-1" class="xref-bibr" href="#ref-57">57</a>
      </sup>.
     </p>
    </div>
    <div id="sec-20" class="subsection">
     <h3>4.12. Statistical analysis</h3>
     <p id="p-51">The assays were performed blinded by one professional, codified and then read by another professional. All experiments were carried out at least three independent times, including a minimum of two technical replicates in each assay. The dose-response curves used to calculate EC
      <sub>50</sub> and CC
      <sub>50</sub> values were generated by variable slope plot from Prism GraphPad software 8.0. The equations to fit the best curve were generated based on R
      <sup>2</sup> values ≥ 0.9. Student’s T-test was used to access statistically significant 
      <em>P</em> values &lt;;0.05. The statistical analyses specific to each software program used in the bioinformatics analysis are described above.
     </p>
    </div>
   </div>
   <div class="section" id="sec-21">
    <h2 class="">Author contributions</h2>
    <p id="p-52">Experimental execution and analysis – NFR, CQS, CRL, FSS, ACF, MM, ARM, CSF, VCS, SSGD, MM, AM</p>
    <p id="p-53">Data analysis, manuscript preparation and revision – NFR, CQS, ACF, CSF, CRL, FSS, CRA, FAB, MMS, PTB, TMLS</p>
    <p id="p-54">Conceptualized the experiments – NFR, CQS, TMLS Study coordination – TMLS</p>
    <p id="p-55">Manuscript preparation and revision – PTB, TMLS</p>
   </div>
   <div class="section ack" id="ack-1">
    <h2 class="">Acknowledgments</h2>
    <p id="p-56">Thanks are due to Dr. Carmen Beatriz Wagner Giacoia Gripp for assessments related to BSL3 facility. This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). This study was financed in part by the Coordenac□ão de Aperfeic□oamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. Funding was also provided by CNPq, CAPES and FAPERJ through the National Institutes of Science and Technology Program (INCT) to Carlos Morel (INCT-IDPN). Thanks are due to Oswaldo Cruz Foundation/FIOCRUZ under the auspicious of Inova program. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p>
    <p id="p-57">
     <strong>The authors declare no competing financial interests.</strong>
    </p>
   </div>
   <div class="section fn-group" id="fn-group-1">
    <h2>Footnotes</h2>
    <ul>
     <li class="fn-update fn-group-summary-of-updates" id="fn-2">
      <p id="p-4">Authors' affiliations were corrected</p>
     </li>
    </ul>
   </div>
   <div class="section ref-list" id="ref-list-1">
    <h2 class="">References</h2>
    <ol class="cit-list ref-use-labels">
     <li>
      <span class="ref-label">1.</span>
      <a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text" id="ref-1">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.1" data-doi="10.1016/S0065-3527(06)66005-3">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Masters</span>, 
          <span class="cit-name-given-names">P. S.</span>
         </span>
         <span class="cit-article-title">The molecular biology of coronaviruses</span>. 
         <abbr class="cit-jnl-abbrev">Adv. Virus Res</abbr>. 
         <span class="cit-vol">66</span>, 
         <span class="cit-fpage">193</span>–
         <span class="cit-lpage">292</span> (
         <span class="cit-pub-date">2006</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAdvances%2Bin%2Bvirus%2Bresearch%26rft.stitle%253DAdv%2BVirus%2BRes%26rft.aulast%253DMasters%26rft.auinit1%253DP.%2BS.%26rft.volume%253D66%26rft.spage%253D193%26rft.epage%253D292%26rft.atitle%253DThe%2Bmolecular%2Bbiology%2Bof%2Bcoronaviruses.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0065-3527%252806%252966005-3%26rft_id%253Dinfo%253Apmid%252F16877062%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/S0065-3527(06)66005-3&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=16877062&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000240137400005&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">2.</span>
      <a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text" id="ref-2">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.2" data-doi="10.1038/s41579-018-0118-9">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Cui</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>, 
          <span class="cit-name-given-names">F.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Shi</span>, 
          <span class="cit-name-given-names">Z.-L.</span>
         </span>
         <span class="cit-article-title">Origin and evolution of pathogenic coronaviruses</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Rev. Microbiol</abbr>. 
         <span class="cit-vol">17</span>, 
         <span class="cit-fpage">181</span>–
         <span class="cit-lpage">192</span> (
         <span class="cit-pub-date">2019</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNat.%2BRev.%2BMicrobiol%26rft.volume%253D17%26rft.spage%253D181%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41579-018-0118-9%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/s41579-018-0118-9&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">3.</span>
      <a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text" id="ref-3">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.3" data-doi="10.1038/s41586-020-2169-0">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Lam</span>, 
          <span class="cit-name-given-names">T. T.-Y.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins</span>. 
         <abbr class="cit-jnl-abbrev">Nature</abbr> (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1038/s41586-020-2169-0</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNature%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41586-020-2169-0%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/s41586-020-2169-0&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">4.</span>
      <a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text" id="ref-4">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.04.04.020925v2.4">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">WHO | Middle East respiratory syndrome coronavirus (MERS-CoV)</span>. 
         <span class="cit-source">WHO</span>
         <a href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</a> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">5.</span>
      <a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text" id="ref-5">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.04.04.020925v2.5">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">WHO</span> | 
         <span class="cit-article-title">Severe Acute Respiratory Syndrome (SARS)</span>. 
         <span class="cit-source">WHO</span>
         <a href="https://www.who.int/csr/sars/en/">https://www.who.int/csr/sars/en/</a> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">6.</span>
      <a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text" id="ref-6">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.6">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Dong</span>, 
          <span class="cit-name-given-names">E.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Du</span>, 
          <span class="cit-name-given-names">H.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Gardner</span>, 
          <span class="cit-name-given-names">L.</span>
         </span>
         <span class="cit-article-title">An interactive web-based dashboard to track COVID-19 in real time</span>. 
         <abbr class="cit-jnl-abbrev">Lancet Infect. Dis</abbr>. 
         <span class="cit-vol">0</span>, (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">7.</span>
      <a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text" id="ref-7">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.7">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Romer</span>, 
          <span class="cit-name-given-names">P.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Garber</span>, 
          <span class="cit-name-given-names">A. M.</span>
         </span>
         <span class="cit-article-title">Opinion | Will Our Economy Die From Coronavirus?</span>
         <abbr class="cit-jnl-abbrev">The New York Times</abbr> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">8.</span>
      <a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text" id="ref-8">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.8" data-doi="10.1038/d41587-020-00003-1">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Harrison</span>, 
          <span class="cit-name-given-names">C.</span>
         </span>
         <span class="cit-article-title">Coronavirus puts drug repurposing on the fast track</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Biotechnol</abbr>. (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1038/d41587-020-00003-1</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNat.%2BBiotechnol%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fd41587-020-00003-1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/d41587-020-00003-1&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">9.</span>
      <a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text" id="ref-9">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.9">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Organization</span>, 
          <span class="cit-name-given-names">W. H.</span>
         </span>
         <abbr class="cit-jnl-abbrev">WHO R&amp;;D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020</abbr>. (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">10.</span>
      <a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text" id="ref-10">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.10" data-doi="10.1128/CMR.00102-15">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">De Clercq</span>, 
          <span class="cit-name-given-names">E.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>, 
          <span class="cit-name-given-names">G.</span>
         </span>
         <span class="cit-article-title">Approved Antiviral Drugs over the Past 50 Years</span>. 
         <abbr class="cit-jnl-abbrev">Clin Microbiol Rev</abbr>
         <span class="cit-vol">29</span>, 
         <span class="cit-fpage">695</span>–
         <span class="cit-lpage">747</span> (
         <span class="cit-pub-date">2016</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DClinical%2BMicrobiology%2BReviews%26rft.stitle%253DClin.%2BMicrobiol.%2BRev.%26rft.aulast%253DDe%2BClercq%26rft.auinit1%253DE.%26rft.volume%253D29%26rft.issue%253D3%26rft.spage%253D695%26rft.epage%253D747%26rft.atitle%253DApproved%2BAntiviral%2BDrugs%2Bover%2Bthe%2BPast%2B50%2BYears%26rft_id%253Dinfo%253Adoi%252F10.1128%252FCMR.00102-15%26rft_id%253Dinfo%253Apmid%252F27281742%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiY21yIjtzOjU6InJlc2lkIjtzOjg6IjI5LzMvNjk1IjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDQvMDYvMjAyMC4wNC4wNC4wMjA5MjUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">11.</span>
      <a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text" id="ref-11">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.11" data-doi="10.1073/pnas.0403596101">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Wu</span>, 
          <span class="cit-name-given-names">C.-Y.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Small molecules targeting severe acute respiratory syndrome human coronavirus</span>. 
         <abbr class="cit-jnl-abbrev">Proc. Natl. Acad. Sci. U. S. A</abbr>. 
         <span class="cit-vol">101</span>, 
         <span class="cit-fpage">10012</span>–
         <span class="cit-lpage">10017</span> (
         <span class="cit-pub-date">2004</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DProc.%2BNatl.%2BAcad.%2BSci.%2BU.%2BS.%2BA%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.0403596101%26rft_id%253Dinfo%253Apmid%252F15226499%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTAxLzI3LzEwMDEyIjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDQvMDYvMjAyMC4wNC4wNC4wMjA5MjUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">12.</span>
      <a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text" id="ref-12">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.12">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Fehr</span>, 
          <span class="cit-name-given-names">A. R.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Perlman</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>
         <span class="cit-article-title">Coronaviruses: an overview of their replication and pathogenesis</span>. 
         <abbr class="cit-jnl-abbrev">Methods Mol. Biol. Clifton NJ</abbr>
         <span class="cit-vol">1282</span>, 
         <span class="cit-fpage">1</span>–
         <span class="cit-lpage">23</span> (
         <span class="cit-pub-date">2015</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DMethods%2BMol.%2BBiol.%2BClifton%2BNJ%26rft.volume%253D1282%26rft.spage%253D1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">13.</span>
      <a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text" id="ref-13">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.13">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Gong</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment</span>. 
         <abbr class="cit-jnl-abbrev">Expert Opin. Drug Metab. Toxicol</abbr>. 
         <span class="cit-vol">15</span>, 
         <span class="cit-fpage">417</span>–
         <span class="cit-lpage">427</span> (
         <span class="cit-pub-date">2019</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DExpert%2BOpin.%2BDrug%2BMetab.%2BToxicol%26rft.volume%253D15%26rft.spage%253D417%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">14.</span>
      <a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text" id="ref-14">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.14" data-doi="10.1056/NEJMoa2001282">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Cao</span>, 
          <span class="cit-name-given-names">B.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</span>. 
         <abbr class="cit-jnl-abbrev">N. Engl. J. Med</abbr>. (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1056/NEJMoa2001282</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DN.%2BEngl.%2BJ.%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001282%26rft_id%253Dinfo%253Apmid%252F32187464%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1056/NEJMoa2001282&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=32187464&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">15.</span>
      <a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text" id="ref-15">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.15">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Stanley</span>, 
          <span class="cit-name-given-names">T. L.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Effects of Switching from Lopinavir/ritonavir to Atazanavir/ritonavir on Muscle Glucose Uptake and Visceral Fat in HIV Infected Patients</span>. 
         <abbr class="cit-jnl-abbrev">AIDS Lond. Engl</abbr>. 
         <span class="cit-vol">23</span>, 
         <span class="cit-fpage">1349</span>–
         <span class="cit-lpage">1357</span> (
         <span class="cit-pub-date">2009</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAIDS%2BLond.%2BEngl%26rft.volume%253D23%26rft.spage%253D1349%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">16.</span>
      <a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text" id="ref-16">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.16">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Gibert</span>, 
          <span class="cit-name-given-names">C. L.</span>
         </span>
         <span class="cit-article-title">Treatment Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: An Update</span>. 
         <abbr class="cit-jnl-abbrev">Fed. Pract</abbr>. 
         <span class="cit-vol">33</span>, 
         <span class="cit-fpage">31S</span>–
         <span class="cit-lpage">36S</span> (
         <span class="cit-pub-date">2016</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DFed.%2BPract%26rft.volume%253D33%26rft.spage%253D31S%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">17.</span>
      <a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text" id="ref-17">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.17">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Dayer</span>, 
          <span class="cit-name-given-names">M. R.</span>
         </span>
         <abbr class="cit-jnl-abbrev">Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective</abbr>. 
         <span class="cit-vol">16</span>.
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">18.</span>
      <a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text" id="ref-18">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.18" data-doi="10.1128/AAC.00267-13">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Gautam</span>, 
          <span class="cit-name-given-names">N.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Preclinical pharmacokinetics and tissue distribution of longacting nanoformulated antiretroviral therapy</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob. Agents Chemother</abbr>. 
         <span class="cit-vol">57</span>, 
         <span class="cit-fpage">3110</span>–
         <span class="cit-lpage">3120</span> (
         <span class="cit-pub-date">2013</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob.%2BAgents%2BChemother%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.00267-13%26rft_id%253Dinfo%253Apmid%252F23612193%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjU3LzcvMzExMCI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzA0LzA2LzIwMjAuMDQuMDQuMDIwOTI1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">19.</span>
      <a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text" id="ref-19">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.19">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Song</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Protective Effect of Atazanavir Sulphate Against Pulmonary Fibrosis In Vivo and In Vitro</span>. 
         <abbr class="cit-jnl-abbrev">Basic Clin. Pharmacol. Toxicol</abbr>. 
         <span class="cit-vol">122</span>, 
         <span class="cit-fpage">199</span>–
         <span class="cit-lpage">207</span> (
         <span class="cit-pub-date">2018</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBasic%2BClin.%2BPharmacol.%2BToxicol%26rft.volume%253D122%26rft.spage%253D199%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">20.</span>
      <a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text" id="ref-20">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.20" data-doi="10.1038/s41422-020-0282-0">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span>. 
         <abbr class="cit-jnl-abbrev">Cell Res</abbr>. 
         <span class="cit-vol">30</span>, 
         <span class="cit-fpage">269</span>–
         <span class="cit-lpage">271</span> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DCell%2BRes%26rft.volume%253D30%26rft.spage%253D269%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41422-020-0282-0%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/s41422-020-0282-0&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=http://www.n&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">21.</span>
      <a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text" id="ref-21">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.21" data-doi="10.1016/j.ijantimicag.2020.105949">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Gautret</span>, 
          <span class="cit-name-given-names">P.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</span>. 
         <abbr class="cit-jnl-abbrev">Int. J. Antimicrob. Agents 105949</abbr> (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1016/j.ijantimicag.2020.105949</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DInt.%2BJ.%2BAntimicrob.%2BAgents%2B105949%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijantimicag.2020.105949%26rft_id%253Dinfo%253Apmid%252F32205204%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.ijantimicag.2020.105949&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=32205204&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">22.</span>
      <a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text" id="ref-22">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.22">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhou</span>, 
          <span class="cit-name-given-names">F.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</span>. 
         <abbr class="cit-jnl-abbrev">The Lancet</abbr>
         <span class="cit-vol">395</span>, 
         <span class="cit-fpage">1054</span>–
         <span class="cit-lpage">1062</span> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DThe%2BLancet%26rft.volume%253D395%26rft.spage%253D1054%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">23.</span>
      <a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text" id="ref-23">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.23" data-doi="10.1007/s00281-016-0558-0">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Newton</span>, 
          <span class="cit-name-given-names">A. H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Cardani</span>, 
          <span class="cit-name-given-names">A.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Braciale</span>, 
          <span class="cit-name-given-names">T. J.</span>
         </span>
         <span class="cit-article-title">The host immune response in respiratory virus infection: balancing virus clearance and immunopathology</span>. 
         <abbr class="cit-jnl-abbrev">Semin. Immunopathol</abbr>. 
         <span class="cit-vol">38</span>, 
         <span class="cit-fpage">471</span>–
         <span class="cit-lpage">482</span> (
         <span class="cit-pub-date">2016</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DSemin.%2BImmunopathol%26rft.volume%253D38%26rft.spage%253D471%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs00281-016-0558-0%26rft_id%253Dinfo%253Apmid%252F26965109%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1007/s00281-016-0558-0&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=26965109&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">24.</span>
      <a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text" id="ref-24">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.24" data-doi="10.1016/S1473-3099(16)00125-0">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Solomon</span>, 
          <span class="cit-name-given-names">T.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Baylis</span>, 
          <span class="cit-name-given-names">M.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Brown</span>, 
          <span class="cit-name-given-names">D.</span>
         </span>
         <span class="cit-article-title">Zika virus and neurological diseaseapproaches to the unknown</span>. 
         <abbr class="cit-jnl-abbrev">Lancet Infect Dis</abbr>
         <span class="cit-vol">16</span>, 
         <span class="cit-fpage">402</span>–
         <span class="cit-lpage">4</span> (
         <span class="cit-pub-date">2016</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DLancet%2BInfect%2BDis%26rft.volume%253D16%26rft.spage%253D402%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1473-3099%252816%252900125-0%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/S1473-3099(16)00125-0&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">25.</span>
      <a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text" id="ref-25">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.25" data-doi="10.1371/journal.pntd.0007072">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">de Freitas</span>, 
          <span class="cit-name-given-names">C. S.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo</span>. 
         <abbr class="cit-jnl-abbrev">PLoS Negl Trop Dis</abbr>
         <span class="cit-vol">13</span>, 
         <span class="cit-fpage">e0007072</span> (
         <span class="cit-pub-date">2019</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DPLoS%2BNegl%2BTrop%2BDis%26rft.volume%253D13%26rft.spage%253De0007072%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pntd.0007072%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1371/journal.pntd.0007072&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">26.</span>
      <div class="cit ref-cit ref-journal no-rev-xref" id="cit-2020.04.04.020925v2.26" data-doi="10.1128/aac.01389-18">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ferreira</span>, 
          <span class="cit-name-given-names">A. C.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob Agents Chemother</abbr> (
         <span class="cit-pub-date">2018</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1128/aac.01389-18</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob%2BAgents%2BChemother%26rft_id%253Dinfo%253Adoi%252F10.1128%252Faac.01389-18%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1128/aac.01389-18&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">27.</span>
      <div class="cit ref-cit ref-journal no-rev-xref" id="cit-2020.04.04.020925v2.27" data-doi="10.1038/s41598-017-09797-8">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ferreira</span>, 
          <span class="cit-name-given-names">A. C.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae</span>. 
         <abbr class="cit-jnl-abbrev">Sci. Rep</abbr>. 
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">9409</span> (
         <span class="cit-pub-date">2017</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DSci.%2BRep%26rft.volume%253D7%26rft.spage%253D9409%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41598-017-09797-8%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/s41598-017-09797-8&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">28.</span>
      <div class="cit ref-cit ref-journal no-rev-xref" id="cit-2020.04.04.020925v2.28" data-doi="10.1038/srep40920">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Sacramento</span>, 
          <span class="cit-name-given-names">C. Q.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication</span>. 
         <abbr class="cit-jnl-abbrev">Sci Rep</abbr>
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">40920</span> (
         <span class="cit-pub-date">2017</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DSci%2BRep%26rft.volume%253D7%26rft.spage%253D40920%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fsrep40920%26rft_id%253Dinfo%253Apmid%252FPMCPMC524187%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/srep40920&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=PMCPMC524187&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">29.</span>
      <a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29. in text" id="ref-29">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.29" data-doi="10.1136/bmjopen-2018-027207">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Figueiredo-Mello</span>, 
          <span class="cit-name-given-names">C.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)</span>. 
         <abbr class="cit-jnl-abbrev">BMJ Open</abbr>
         <span class="cit-vol">9</span>, 
         <span class="cit-fpage">e027207</span> (
         <span class="cit-pub-date">2019</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBMJ%2BOpen%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fbmjopen-2018-027207%26rft_id%253Dinfo%253Apmid%252F31772079%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMjoiOS8xMS9lMDI3MjA3IjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDQvMDYvMjAyMC4wNC4wNC4wMjA5MjUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">30.</span>
      <a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30. in text" id="ref-30">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.04.04.020925v2.30">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">UN health chief announces global ‘solidarity trial’ to jumpstart search for COVID-19 treatment</span>. 
         <span class="cit-source">UN News</span>
         <a href="https://news.un.org/en/story/2020/03/1059722">https://news.un.org/en/story/2020/03/1059722</a> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">31.</span>
      <a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31. in text" id="ref-31">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.31" data-doi="10.1186/s40779-020-0233-6">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Jin</span>, 
          <span class="cit-name-given-names">Y.-H.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)</span>. 
         <abbr class="cit-jnl-abbrev">Mil. Med. Res</abbr>. 
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">4</span> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DMil.%2BMed.%2BRes%26rft.volume%253D7%26rft.spage%253D4%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs40779-020-0233-6%26rft_id%253Dinfo%253Apmid%252F32029004%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1186/s40779-020-0233-6&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=32029004&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">32.</span>
      <a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32. in text" id="ref-32">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.32" data-doi="10.1038/s41467-019-13889-6">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Sheahan</span>, 
          <span class="cit-name-given-names">T. P.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Commun</abbr>. 
         <span class="cit-vol">11</span>, 
         <span class="cit-fpage">1</span>–
         <span class="cit-lpage">14</span> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNat.%2BCommun%26rft.volume%253D11%26rft.spage%253D1%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41467-019-13889-6%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/s41467-019-13889-6&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">33.</span>
      <a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33. in text" id="ref-33">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.33">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Lv</span>, 
          <span class="cit-name-given-names">Z.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chu</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>
         <span class="cit-article-title">HIV protease inhibitors: a review of molecular selectivity and toxicity</span>. 
         <abbr class="cit-jnl-abbrev">HIVAIDS Auckl. NZ</abbr>
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">95</span>–
         <span class="cit-lpage">104</span> (
         <span class="cit-pub-date">2015</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DHIVAIDS%2BAuckl.%2BNZ%26rft.volume%253D7%26rft.spage%253D95%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">34.</span>
      <a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34. in text" id="ref-34">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.34" data-doi="10.1016/j.jchromb.2011.06.032">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Huang</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues</span>. 
         <abbr class="cit-jnl-abbrev">J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci</abbr>. 
         <span class="cit-vol">879</span>, 
         <span class="cit-fpage">2332</span>–
         <span class="cit-lpage">2338</span> (
         <span class="cit-pub-date">2011</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bchromatography.%2BB%252C%2BAnalytical%2Btechnologies%2Bin%2Bthe%2Bbiomedical%2Band%2Blife%2Bsciences%26rft.stitle%253DJ%2BChromatogr%2BB%2BAnalyt%2BTechnol%2BBiomed%2BLife%2BSci%26rft.aulast%253DHuang%26rft.auinit1%253DJ.%26rft.volume%253D879%26rft.issue%253D23%26rft.spage%253D2332%26rft.epage%253D2338%26rft.atitle%253DUPLC-MS%252FMS%2Bquantification%2Bof%2Bnanoformulated%2Britonavir%252C%2Bindinavir%252C%2Batazanavir%252C%2Band%2Befavirenz%2Bin%2Bmouse%2Bserum%2Band%2Btissues.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jchromb.2011.06.032%26rft_id%253Dinfo%253Apmid%252F21752731%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.jchromb.2011.06.032&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=21752731&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">35.</span>
      <a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference 35. in text" id="ref-35">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.35" data-doi="10.1101/2020.01.31.929547">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Beck</span>, 
          <span class="cit-name-given-names">B. R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shin</span>, 
          <span class="cit-name-given-names">B.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Choi</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Park</span>, 
          <span class="cit-name-given-names">S.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Kang</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>
         <span class="cit-article-title">Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model</span>. 
         <abbr class="cit-jnl-abbrev">bioRxiv 2020.01.31.929547</abbr> (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1101/2020.01.31.929547</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DbioRxiv%2B2020.01.31.929547%26rft_id%253Dinfo%253Adoi%252F10.1101%252F2020.01.31.929547%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYmlvcnhpdiI7czo1OiJyZXNpZCI7czoxOToiMjAyMC4wMS4zMS45Mjk1NDd2MSI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzA0LzA2LzIwMjAuMDQuMDQuMDIwOTI1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">36.</span>
      <a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36. in text" id="ref-36">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.36" data-doi="10.1073/pnas.1835675100">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Yang</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</span>. 
         <abbr class="cit-jnl-abbrev">Proc. Natl. Acad. Sci. U. S. A</abbr>. 
         <span class="cit-vol">100</span>, 
         <span class="cit-fpage">13190</span>–
         <span class="cit-lpage">13195</span> (
         <span class="cit-pub-date">2003</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DProc.%2BNatl.%2BAcad.%2BSci.%2BU.%2BS.%2BA%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.1835675100%26rft_id%253Dinfo%253Apmid%252F14585926%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTAwLzIzLzEzMTkwIjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDQvMDYvMjAyMC4wNC4wNC4wMjA5MjUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">37.</span>
      <a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37. in text" id="ref-37">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.37">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Macchiagodena</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Pagliai</span>, 
          <span class="cit-name-given-names">M.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Procacci</span>, 
          <span class="cit-name-given-names">P.</span>
         </span>
         <abbr class="cit-jnl-abbrev">Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling</abbr>. (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">38.</span>
      <a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference 38. in text" id="ref-38">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.38" data-doi="10.1016/j.ajpath.2013.06.023">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Gao</span>, 
          <span class="cit-name-given-names">R.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis</span>. 
         <abbr class="cit-jnl-abbrev">Am J Pathol</abbr>
         <span class="cit-vol">183</span>, 
         <span class="cit-fpage">1258</span>–
         <span class="cit-lpage">68</span> (
         <span class="cit-pub-date">2013</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAm%2BJ%2BPathol%26rft.volume%253D183%26rft.spage%253D1258%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ajpath.2013.06.023%26rft_id%253Dinfo%253Apmid%252F23938324%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.ajpath.2013.06.023&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=23938324&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">39.</span>
      <a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference 39. in text" id="ref-39">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.39" data-doi="10.1016/S0171-2985(11)80365-7">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Peschke</span>, 
          <span class="cit-name-given-names">T.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bender</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nain</span>, 
          <span class="cit-name-given-names">M.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Gemsa</span>, 
          <span class="cit-name-given-names">D.</span>
         </span>
         <span class="cit-article-title">Role of macrophage cytokines in influenza A virus infections</span>. 
         <abbr class="cit-jnl-abbrev">Immunobiology</abbr>
         <span class="cit-vol">189</span>, 
         <span class="cit-fpage">340</span>–
         <span class="cit-lpage">55</span> (
         <span class="cit-pub-date">1993</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DImmunobiology%26rft.stitle%253DImmunobiology%26rft.aulast%253DPeschke%26rft.auinit1%253DT.%26rft.volume%253D189%26rft.issue%253D3-4%26rft.spage%253D340%26rft.epage%253D355%26rft.atitle%253DRole%2Bof%2Bmacrophage%2Bcytokines%2Bin%2Binfluenza%2BA%2Bvirus%2Binfections.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0171-2985%252811%252980365-7%26rft_id%253Dinfo%253Apmid%252F8125516%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/S0171-2985(11)80365-7&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=8125516&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=A1993MM77000005&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">40.</span>
      <a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference 40. in text" id="ref-40">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.40" data-doi="10.1007/s00281-017-0629-x">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Channappanavar</span>, 
          <span class="cit-name-given-names">R.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Perlman</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>
         <span class="cit-article-title">Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</span>. 
         <abbr class="cit-jnl-abbrev">Semin. Immunopathol</abbr>. 
         <span class="cit-vol">39</span>, 
         <span class="cit-fpage">529</span>–
         <span class="cit-lpage">539</span> (
         <span class="cit-pub-date">2017</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DSemin.%2BImmunopathol%26rft.volume%253D39%26rft.spage%253D529%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs00281-017-0629-x%26rft_id%253Dinfo%253Apmid%252F28466096%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1007/s00281-017-0629-x&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=28466096&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">41.</span>
      <a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference 41. in text" id="ref-41">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.41" data-doi="10.1007/s00705-010-0716-y">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Monteerarat</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Induction of TNF-alpha in human macrophages by avian and human influenza viruses</span>. 
         <abbr class="cit-jnl-abbrev">Arch Virol</abbr>
         <span class="cit-vol">155</span>, 
         <span class="cit-fpage">1273</span>–
         <span class="cit-lpage">9</span> (
         <span class="cit-pub-date">2010</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DArchives%2Bof%2Bvirology%26rft.stitle%253DArch%2BVirol%26rft.aulast%253DMonteerarat%26rft.auinit1%253DY.%26rft.volume%253D155%26rft.issue%253D8%26rft.spage%253D1273%26rft.epage%253D1279%26rft.atitle%253DInduction%2Bof%2BTNF-alpha%2Bin%2Bhuman%2Bmacrophages%2Bby%2Bavian%2Band%2Bhuman%2Binfluenza%2Bviruses.%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs00705-010-0716-y%26rft_id%253Dinfo%253Apmid%252F20532927%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1007/s00705-010-0716-y&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=20532927&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">42.</span>
      <a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference 42. in text" id="ref-42">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.42">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Reed</span>, 
          <span class="cit-name-given-names">H. L. J.</span>
         </span>,. &amp;;. 
         <span class="cit-auth">
          <span class="cit-name-surname">Muench</span>
         </span>. 
         <span class="cit-article-title">A simple method of estimating fifty percent endpoints</span>. 
         <abbr class="cit-jnl-abbrev">Am J Hyg</abbr>. (
         <span class="cit-pub-date">1938</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">43.</span>
      <a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference 43. in text" id="ref-43">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.04.04.020925v2.43">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">CDC. Coronavirus Disease 2019 (COVID-19)</span>. 
         <span class="cit-source">Centers for Disease Control and Prevention</span>
         <a href="https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html">https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html</a> (
         <span class="cit-pub-date">2020</span>).
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">44.</span>
      <a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference 44. in text" id="ref-44">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.44" data-doi="10.1002/jcc.10128">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Jakalian</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jack</span>, 
          <span class="cit-name-given-names">D. B.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Bayly</span>, 
          <span class="cit-name-given-names">C. I.</span>
         </span>
         <span class="cit-article-title">Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation</span>. 
         <abbr class="cit-jnl-abbrev">J. Comput. Chem</abbr>. 
         <span class="cit-vol">23</span>, 
         <span class="cit-fpage">1623</span>–
         <span class="cit-lpage">1641</span> (
         <span class="cit-pub-date">2002</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcomputational%2Bchemistry%26rft.stitle%253DJ%2BComput%2BChem%26rft.aulast%253DJakalian%26rft.auinit1%253DA.%26rft.volume%253D23%26rft.issue%253D16%26rft.spage%253D1623%26rft.epage%253D1641%26rft.atitle%253DFast%252C%2Befficient%2Bgeneration%2Bof%2Bhigh-quality%2Batomic%2Bcharges.%2BAM1-BCC%2Bmodel%253A%2BII.%2BParameterization%2Band%2Bvalidation.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.10128%26rft_id%253Dinfo%253Apmid%252F12395429%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.10128&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=12395429&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000179022700012&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">45.</span>
      <a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference 45. in text" id="ref-45">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.45" data-doi="10.1002/jcc.20035">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wolf</span>, 
          <span class="cit-name-given-names">R. M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Caldwell</span>, 
          <span class="cit-name-given-names">J. W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kollman</span>, 
          <span class="cit-name-given-names">P. A.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Case</span>, 
          <span class="cit-name-given-names">D. A.</span>
         </span>
         <span class="cit-article-title">Development and testing of a general amber force field</span>. 
         <abbr class="cit-jnl-abbrev">J. Comput. Chem</abbr>. 
         <span class="cit-vol">25</span>, 
         <span class="cit-fpage">1157</span>–
         <span class="cit-lpage">1174</span> (
         <span class="cit-pub-date">2004</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcomputational%2Bchemistry%26rft.stitle%253DJ%2BComput%2BChem%26rft.aulast%253DWang%26rft.auinit1%253DJ.%26rft.volume%253D25%26rft.issue%253D9%26rft.spage%253D1157%26rft.epage%253D1174%26rft.atitle%253DDevelopment%2Band%2Btesting%2Bof%2Ba%2Bgeneral%2Bamber%2Bforce%2Bfield.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.20035%26rft_id%253Dinfo%253Apmid%252F15116359%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.20035&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=15116359&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000221624200007&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">46.</span>
      <a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference 46. in text" id="ref-46">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.46" data-doi="10.1002/jcc.23905">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Allen</span>, 
          <span class="cit-name-given-names">W. J.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">DOCK 6: Impact of new features and current docking performance</span>. 
         <abbr class="cit-jnl-abbrev">J. Comput. Chem</abbr>. 
         <span class="cit-vol">36</span>, 
         <span class="cit-fpage">1132</span>–
         <span class="cit-lpage">1156</span> (
         <span class="cit-pub-date">2015</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BComput.%2BChem%26rft.volume%253D36%26rft.spage%253D1132%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.23905%26rft_id%253Dinfo%253Apmid%252F25914306%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.23905&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=25914306&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">47.</span>
      <a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference 47. in text" id="ref-47">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.47" data-doi="10.1101/2020.02.26.964882">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Jin</span>, 
          <span class="cit-name-given-names">Z.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19</span>. 
         <abbr class="cit-jnl-abbrev">bioRxiv 2020.02.26.964882</abbr> (
         <span class="cit-pub-date">2020</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">10.1101/2020.02.26.964882</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DbioRxiv%2B2020.02.26.964882%26rft_id%253Dinfo%253Adoi%252F10.1101%252F2020.02.26.964882%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYmlvcnhpdiI7czo1OiJyZXNpZCI7czoxOToiMjAyMC4wMi4yNi45NjQ4ODJ2MyI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzA0LzA2LzIwMjAuMDQuMDQuMDIwOTI1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">48.</span>
      <a class="rev-xref-ref" href="#xref-ref-48-1" title="View reference 48. in text" id="ref-48">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.48" data-doi="10.1002/jcc.20084">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Pettersen</span>, 
          <span class="cit-name-given-names">E. F.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">UCSF Chimera--a visualization system for exploratory research and analysis</span>. 
         <abbr class="cit-jnl-abbrev">J. Comput. Chem</abbr>. 
         <span class="cit-vol">25</span>, 
         <span class="cit-fpage">1605</span>–
         <span class="cit-lpage">1612</span> (
         <span class="cit-pub-date">2004</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcomputational%2Bchemistry%26rft.stitle%253DJ%2BComput%2BChem%26rft.aulast%253DPettersen%26rft.auinit1%253DE.%2BF.%26rft.volume%253D25%26rft.issue%253D13%26rft.spage%253D1605%26rft.epage%253D1612%26rft.atitle%253DUCSF%2BChimera--a%2Bvisualization%2Bsystem%2Bfor%2Bexploratory%2Bresearch%2Band%2Banalysis.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.20084%26rft_id%253Dinfo%253Apmid%252F15264254%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.20084&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=15264254&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000223379100005&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">49.</span>
      <a class="rev-xref-ref" href="#xref-ref-49-1" title="View reference 49. in text" id="ref-49">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.49" data-doi="10.1002/jcc.20289">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Phillips</span>, 
          <span class="cit-name-given-names">J. C.</span>
         </span>
         <span class="cit-etal">et al.</span>
         <span class="cit-article-title">Scalable molecular dynamics with NAMD</span>. 
         <abbr class="cit-jnl-abbrev">J. Comput. Chem</abbr>. 
         <span class="cit-vol">26</span>, 
         <span class="cit-fpage">1781</span>–
         <span class="cit-lpage">1802</span> (
         <span class="cit-pub-date">2005</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcomputational%2Bchemistry%26rft.stitle%253DJ%2BComput%2BChem%26rft.aulast%253DPhillips%26rft.auinit1%253DJ.%2BC.%26rft.volume%253D26%26rft.issue%253D16%26rft.spage%253D1781%26rft.epage%253D1802%26rft.atitle%253DScalable%2Bmolecular%2Bdynamics%2Bwith%2BNAMD.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.20289%26rft_id%253Dinfo%253Apmid%252F16222654%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.20289&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=16222654&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000233021400007&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">50.</span>
      <a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference 50. in text" id="ref-50">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.50" data-doi="10.1002/1097-0282(2000)56:4&lt;;257::AID-BIP10029&gt;;3.0.CO;2-W">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">MacKerell</span>, 
          <span class="cit-name-given-names">A. D.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Banavali</span>, 
          <span class="cit-name-given-names">N.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Foloppe</span>, 
          <span class="cit-name-given-names">N.</span>
         </span>
         <span class="cit-article-title">Development and current status of the CHARMM force field for nucleic acids</span>. 
         <abbr class="cit-jnl-abbrev">Biopolymers</abbr>
         <span class="cit-vol">56</span>, 
         <span class="cit-fpage">257</span>–
         <span class="cit-lpage">265</span> (
         <span class="cit-pub-date">2000</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBiopolymers%26rft.stitle%253DBiopolymers%26rft.aulast%253DMacKerell%26rft.auinit1%253DA.%2BD.%26rft.volume%253D56%26rft.issue%253D4%26rft.spage%253D257%26rft.epage%253D265%26rft.atitle%253DDevelopment%2Band%2Bcurrent%2Bstatus%2Bof%2Bthe%2BCHARMM%2Bforce%2Bfield%2Bfor%2Bnucleic%2Bacids.%26rft_id%253Dinfo%253Adoi%252F10.1002%252F1097-0282%25282000%252956%253A4%253C257%253A%253AAID-BIP10029%253E3.0.CO%253B2-W%26rft_id%253Dinfo%253Apmid%252F11754339%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/1097-0282(2000)56:4&lt;;257::AID-BIP10029&gt;;3.0.CO;2-W&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=11754339&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000173077900003&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">51.</span>
      <a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference 51. in text" id="ref-51">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.51">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>, 
          <span class="cit-name-given-names">T.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nguyen</span>, 
          <span class="cit-name-given-names">P. H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nasica-Labouze</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Mu</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Derreumaux</span>, 
          <span class="cit-name-given-names">P.</span>
         </span>
         <span class="cit-article-title">Folding Atomistic Proteins in Explicit Solvent Using Simulated Tempering</span>. 
         <abbr class="cit-jnl-abbrev">J. Phys. Chem. B</abbr>
         <span class="cit-vol">119</span>, 
         <span class="cit-fpage">6941</span>–
         <span class="cit-lpage">6951</span> (
         <span class="cit-pub-date">2015</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BPhys.%2BChem.%2BB%26rft.volume%253D119%26rft.spage%253D6941%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">52.</span>
      <div class="cit ref-cit ref-journal no-rev-xref" id="cit-2020.04.04.020925v2.52">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Hoang Viet</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Derreumaux</span>, 
          <span class="cit-name-given-names">P.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Nguyen</span>, 
          <span class="cit-name-given-names">P. H.</span>
         </span>
         <span class="cit-article-title">Communication: Multiple atomistic force fields in a single enhanced sampling simulation</span>. 
         <abbr class="cit-jnl-abbrev">J. Chem. Phys</abbr>. 
         <span class="cit-vol">143</span>, 
         <span class="cit-fpage">021101</span> (
         <span class="cit-pub-date">2015</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BChem.%2BPhys%26rft.volume%253D143%26rft.spage%253D021101%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">53.</span>
      <a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference 53. in text" id="ref-53">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.53" data-doi="10.1126/science.1208351">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Lindorff-Larsen</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Piana</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Dror</span>, 
          <span class="cit-name-given-names">R. O.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Shaw</span>, 
          <span class="cit-name-given-names">D. E.</span>
         </span>
         <span class="cit-article-title">How fast-folding proteins fold</span>. 
         <abbr class="cit-jnl-abbrev">Science</abbr>
         <span class="cit-vol">334</span>, 
         <span class="cit-fpage">517</span>–
         <span class="cit-lpage">520</span> (
         <span class="cit-pub-date">2011</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DScience%26rft.stitle%253DScience%26rft.aulast%253DLindorff-Larsen%26rft.auinit1%253DK.%26rft.volume%253D334%26rft.issue%253D6055%26rft.spage%253D517%26rft.epage%253D520%26rft.atitle%253DHow%2BFast-Folding%2BProteins%2BFold%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fscience.1208351%26rft_id%253Dinfo%253Apmid%252F22034434%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzMzQvNjA1NS81MTciO3M6NDoiYXRvbSI7czo0ODoiL2Jpb3J4aXYvZWFybHkvMjAyMC8wNC8wNi8yMDIwLjA0LjA0LjAyMDkyNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">54.</span>
      <a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference 54. in text" id="ref-54">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.54" data-doi="1.445869">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Jorgensen</span>, 
          <span class="cit-name-given-names">W. L.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chandrasekhar</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Madura</span>, 
          <span class="cit-name-given-names">J. D.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Impey</span>, 
          <span class="cit-name-given-names">R. W.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Klein</span>, 
          <span class="cit-name-given-names">M. L.</span>
         </span>
         <abbr class="cit-jnl-abbrev">Comparison of simple potential functions for simulating liquid water</abbr>. (
         <span class="cit-pub-date">1998</span>)
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">doi:</span>
         <span class="cit-pub-id cit-pub-id-doi">1.445869</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DComparison%2Bof%2Bsimple%2Bpotential%2Bfunctions%2Bfor%2Bsimulating%2Bliquid%2Bwater%26rft_id%253Dinfo%253Adoi%252F1.445869%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=1.445869&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">55.</span>
      <a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference 55. in text" id="ref-55">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.55" data-doi="10.1063/1.464397">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Darden</span>, 
          <span class="cit-name-given-names">T.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">York</span>, 
          <span class="cit-name-given-names">D.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Pedersen</span>, 
          <span class="cit-name-given-names">L.</span>
         </span>
         <span class="cit-article-title">Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems</span>. 
         <abbr class="cit-jnl-abbrev">J. Chem. Phys</abbr>. 
         <span class="cit-vol">98</span>, 
         <span class="cit-fpage">10089</span>–
         <span class="cit-lpage">10092</span> (
         <span class="cit-pub-date">1993</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BChem.%2BPhys%26rft.volume%253D98%26rft.spage%253D10089%26rft_id%253Dinfo%253Adoi%252F10.1063%252F1.464397%26rft_id%253Dinfo%253Apmid%252F10.1063%252F1.46%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1063/1.464397&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1063/1.46&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=A1993LG10100091&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">56.</span>
      <a class="rev-xref-ref" href="#xref-ref-56-1" title="View reference 56. in text" id="ref-56">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.56" data-doi="10.1016/0003-2697(80)90338-3">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Heussen</span>, 
          <span class="cit-name-given-names">C.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Dowdle</span>, 
          <span class="cit-name-given-names">E. B.</span>
         </span>
         <span class="cit-article-title">Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates</span>. 
         <abbr class="cit-jnl-abbrev">Anal. Biochem</abbr>. 
         <span class="cit-vol">102</span>, 
         <span class="cit-fpage">196</span>–
         <span class="cit-lpage">202</span> (
         <span class="cit-pub-date">1980</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAnalytical%2Bbiochemistry%26rft.stitle%253DAnal%2BBiochem%26rft.aulast%253DHeussen%26rft.auinit1%253DC.%26rft.volume%253D102%26rft.issue%253D1%26rft.spage%253D196%26rft.epage%253D202%26rft.atitle%253DElectrophoretic%2Banalysis%2Bof%2Bplasminogen%2Bactivators%2Bin%2Bpolyacrylamide%2Bgels%2Bcontaining%2Bsodium%2Bdodecyl%2Bsulfate%2Band%2Bcopolymerized%2Bsubstrates.%26rft_id%253Dinfo%253Adoi%252F10.1016%252F0003-2697%252880%252990338-3%26rft_id%253Dinfo%253Apmid%252F7188842%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/0003-2697(80)90338-3&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=7188842&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F04%2F06%2F2020.04.04.020925.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=A1980JG14100032&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">57.</span>
      <a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference 57. in text" id="ref-57">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.04.04.020925v2.57">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Alves</span>, 
          <span class="cit-name-given-names">C. R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Marzochi</span>, 
          <span class="cit-name-given-names">M. C.</span>
         </span> &amp;; 
         <span class="cit-auth">
          <span class="cit-name-surname">Giovanni-de-Simone</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>
         <span class="cit-article-title">Heterogeneity of cysteine proteinases in Leishmania braziliensis and Leishmania major</span>. 
         <abbr class="cit-jnl-abbrev">Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas E Biol</abbr>. 
         <span class="cit-vol">26</span>, 
         <span class="cit-fpage">167</span>–
         <span class="cit-lpage">171</span> (
         <span class="cit-pub-date">1993</span>).
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBraz.%2BJ.%2BMed.%2BBiol.%2BRes.%2BRev.%2BBras.%2BPesqui.%2BMedicas%2BE%2BBiol%26rft.volume%253D26%26rft.spage%253D167%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
    </ol>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
